A Novel Binding Protein for Fibroblast Growth Factors (FGF-BP2):Cloning, Expression Profile, Tumorigenic Activity and Regulation of Gene Expression by Fetal Bovine Serum and Retinoic Acid. by Schmidt, Joachim
 
 
Aus dem  
       
Institut für Pharmakologie und Toxikologie  
der Philipps- Universität Marburg 
 
Geschäftsführender Direktor: Prof. Dr. T. Gudermann 
 
 
 
 
 
 
 
A Novel Binding Protein for Fibroblast Growth Factors (FGF-BP2): 
 
Cloning, Expression Profile, Tumorigenic Activity and Regulation of 
 
Gene Expression by Fetal Bovine Serum and Retinoic Acid. 
 
 
       
 
 
       
Inaugural-Dissertation  
zur Erlangung des Doktorgrades der gesamten Medizin dem Fachbereich 
Medizin der Philipps-Universität Marburg 
 
 
 
 
vorgelegt von 
 
Joachim Schmidt 
 
aus Plettenberg 
 
 
Marburg, 2003 
 
 
 
 
 
Angenommen vom Fachbereich Humanmedizin der Philipps-Universität Marburg am  
 
16. Oktober 2003. 
 
Gedruckt mit Genehmigung des Fachbereichs. 
 
 
 
Dekan: Prof. Dr. med. Bernhard Maisch 
 
Referent: Prof. Dr. med. Frank Czubayko 
 
Correferent: Prof. Dr. med Diethard Gemsa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Eltern 
Gerhard und Annemarie Schmidt  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          ACKNOWLEDGEMENTS 
 
This doctorial thesis was completed in the laboratory and under the supervision of 
 
Prof. Dr. med. Anton Wellstein, MD PhD 
Dept. of Oncology 
Lombardi Cancer Center, TRB E315 
Georgetown University Medical Center 
3970 Reservoir Rd., N.W. 
Washington, DC, 20007 
USA 
 
First and foremost I would like to acknowledge my mentors Prof. Dr. Anton Wellstein 
and Prof. Dr. Frank Czubayko. Both of them made an invaluable contribution to my 
education with their supervision, their enthusiasm for science and their candid 
encouragement. Above all I would like to thank Prof. Wellstein for giving me the great 
and generous opportunity to work in his Laboratory at Georgetown University, 
Washington D.C., USA. I am very appreciative for having had the chance to experience 
the excitement of scientific investigation in an institute of this excellence.  
I would like to thank Dr. Quang Nguyen who helped me with my experiments. Especially 
the soft agar assay and FGF-BP-2 expression data were gained under his direction. Also I 
wish to acknowledge Dr. Claudius Malerczyk, Dr. Anke Schulte, Dr. Heinz-Joachim List 
and Christine Coticchia.  
In particular I would like to thank Dr. Achim Aigner, Dr. Violaine Harris and Dr. George 
Mashour for their unfailing support throughout the project and for correcting this 
dissertation. They taught me a great deal about both science and life during an 
unforgettable year in Washington and have become good friends ever since. 
Again I wish to acknowledge Prof. Czubayko as my mentor in Marburg, who has been of 
continuous and gracious support. 
Finally I wish to thank my parents who always supported my endeavors with love and 
generosity. Nothing in my medical career would have ever been possible without them.  
Table of Contents  I 
 
     TABLE OF CONTENTS  
 
 
 
Title Page            
 
Dedication            
 
Acknowledgements            
 
1. Introduction         1 
 
1.1 Cancer and Tumor Growth       2 
1.2 Tumor Angiogenesis and Metastasis     2 
1.3. The Role of Fibroblast Growth Factors (FGFs) 
and a Binding Protein for FGF (FGF-BP1)    5 
1.4 FGF-BP1 is a Carrier for Immobilized FGFs    6 
1.5 A novel secreted Protein with Similarities  
to FGF-BP1 (FGF-BP2)       8 
1.6 FGF-BP1 Expression in Normal and Neoplastic Tissues  10 
1.7 Mouse FGF-BP1 and its Regulation during Embryonic 
Development and Skin Carcinogenesis    12 
1.8 Regulation of FGF-BP1 by Fetal Bovine Serum,  
EGF, and TPA       14 
1.9 Regulation of FGF-BP1 by Retinoids    16 
1.10 The Objective of this Study      18 
 
Table of Contents  II 
 
2. Material          19  
 
2.1 Chemicals        20 
2.2 Working Materials and Apparatus     21 
2.3 Enzymes        22 
2.4   Molecular Weight Standards     22 
2.5   Vectors        22 
2.6   cDNA Probes for Northern Blot Analysis    22 
2.7 Molecular Biology Reagents     23 
2.8 Kits and Reagents       23 
2.9 Radioisotopes       23 
2.10 Bacterial Cells       23 
2.11 Bacterial Growth Media and Plates    24 
2.12 Cell Culture Materials      24 
2.13 Mammalian Cell Lines      25 
2.14 Buffers and Solutions      27 
2.15 Northern Blot Solutions      28 
2.16 Compounds for Cell Treatments     28 
   
3. Methods          29  
 
3.1 General Laboratory Techniques     30 
3.1.1. Sterilization of Solutions and Work Materials  30 
3.1.2. Determination of DNA and RNA Concentrations  30 
3.1.3. Work with RNA      30 
3.1.4. Work with DNA      31 
3.1.5. Work with Radioactive Isotopes     31 
3.1.6. Gel Electrophoresis of Nucleic Acids   31 
3.1.7. Work with Bacteria       32 
3.1.8. Work with Mammalian Cell Lines    33 
Table of Contents  III 
 
3.2  The FGF-BP2 cDNA BAC Clone     34 
3.3  Cloning of the FGF-BP2 cDNA into the Vector pCR® 3.1  35 
3.3.1 Restriction Digest of the Expression Vector pC4  35 
3.3.2 Gel Extraction       35 
3.3.3 Linerization of the Vector pCR® 3.1    36 
3.3.4 Ligation of the FGF-BP2 cDNA into the Vector pCR® 3.1 36 
3.4 Transformation of the DH5α ™ Cells with the BP2 Plasmid 37 
3.5 DNA Plasmid Purification      37 
3.5.1. Qiagen Miniprep DNA Isolation    38 
3.5.2. Qiagen Maxiprep DNA Isolation    38 
3.6 Sequencing of the FGF-BP2 ORF     
 39 
3.7 Stable Transfection of the Cell Line SW13   39 
3.8 Soft Agar Growth Assay      40 
3.9 Preparation of cDNA Probes for Northern Blot Analysis  41 
3.9.1. DNA Isolation       41 
3.9.2. Digestion of the FGF-BP2 Fragment    42 
3.9.3. Gel Extraction       42 
3.9.4. Radioactive Labeling of the Probe    42 
3.10 RNA Isolation from Mammalian Cell Lines    43 
3.10.1. Homogenization       43 
3.10.2. Extraction       44 
3.10.3. Precipitation        44 
3.10.4. Washing       44 
3.11. Northern Blot Analysis       45 
3.11.1 Preparation and Electrophoresis of RNA Samples  45 
3.11.2 RNA Transfer to Nylon Membrane    45 
3.11.3 RNA Fixation to the Nylon Membrane   46 
3.11.4 Prehybridization      46 
3.11.5 Hybridization        47 
Table of Contents  IV 
3.11.6 Washing       47 
3.11.7 Autoradiography of Hybridized Membranes   48 
3.12 Treatment of Cell Lines with EGF, TPA, Fetal Bovine  
Serum and all-trans-retinoic Acid     48 
 
4. Results          50 
 
4.1 Genomic Sequence Analysis of FGF-BPs    51 
4.2 Cloning of the FGF-BP2 ORF into the Vector pCR® 3.1  52 
4.3 Transformation of the DH5α ™ Cells with the FGF-BP2  
Plasmid and Purification of the Plasmid    53 
4.4 Sequence Analysis of the subcloned FGF-BP2 and  
Comparison to FGF-BP1      53 
4.5 Generating a Hybridization Probe for  
Northern Blot Analysis      54 
4.6 Stable Transfection of the Cell Line SW 13 with  
the FGF-BP2 cDNA       55 
4.7 FGF-BP2 Expression in Normal Tissues and  
Tumor Cell Lines       56 
4.7.1 FGF-BP2 Expression in Normal Tissues   57 
4.7.2 Comparison of FGF-BP1 and FGF-BP2 Expression  
in Normal Tissue      59 
4.7.3 FGF-BP2 Expression in Tumor Cell Lines   61 
4.7.4 Comparison of FGF-BP1 and FGF-BP2 Expression  
in Tumor Cell Lines      62 
4.8    The Regulation of FGF-BP2 mRNA Expression by  
   Serum and all-trans-retinoic Acid.     63 
4.8.1 FGF-BP2 Serum Regulation     64 
4.8.2 FGF-BP2 Regulation by all-trans Retinoic Acid (tRA) 66 
4.9       Biological Activity of FGF-BP2 transfected SW-13 Cells in  
            Soft Agar Assays       74 
Table of Contents  V 
 
5. Discussion         76 
 
5.1 Genomic Sequence Analysis of FGF-BPs    77 
5.2 Biochemical Characterization of Recombinant  
Human FGF-BP2       77 
5.3 FGF-BP2 induced Tumor Growth in Athymic Nude Mice 79 
5.4 FGF-BP2 Expression in Normal Tissue and  
in Tumor cell Lines       80 
5.5 Comparison of FGF-BP1 and FGF-BP2 Expression in  
Normal Tissue and in Tumor Cell Lines    82 
5.6       Skin Carcinogenesis and Expression of FGF-BP2 in  
Human Melanoma Tissue      84 
5.7 The in vitro Regulation of FGF-BP2 byFetal Bovine Serum,  
EGF and TPA       85 
5.8       The in vitro Regulation of FGF-BP2 by  
all-trans Retinoic Acid      87 
5.9       Biological Activity of FGF-BP2 transfected SW-13 Cells  
in Soft Agar Assays       88 
 
6. Abstract          93  
 
7. References         96  
 
8.Abbreviations         106  
 
 
Curriculum vitae / Akademische Lehrer / Ehrenwörtliche Erklärung / 
 
 
Table of Contents  VI 
 
         LIST OF FIGURES  
 
Figure 1: Acquired Capabilities of Cancer     3 
Figure 2: Model of FGF-BP1 Function       7 
Figure 3: Mouse model of skin carcinogenesis      13 
Figure 4: Gene Structures of FGF-BP1 and FGF-BP2     51 
Figure 5: Cloning of the FGF-BP2 cDNA      52 
Figure 6: Deduced Amino Acid Sequence of FGF-BP2    54 
Figure 7: Isolated FGF-BP2 cDNA Fragment      55 
Figure 8: Expression of FGF-BP2 mRNA in SW-13 transfected Cells  56 
Figure 9: Expression of FGF-BP2 mRNA in Normal Adult Tissue I   57 
Figure 10: Expression of FGF-BP2 mRNA in Normal Adult Tissue II   58 
Figure 11: Expression of FGF-BP1 mRNA in Normal Adult Tissue   59 
Figure 12: Distribution and Comparison of FGF-BP1  
and FGF-BP2 mRNA Expression      60 
Figure 13: FGF-BP2 mRNA Expression in Tumor Cell Lines    62 
Figure 14: Fetal Bovine Serum Treatment of 1205LU Melanoma Cells  65 
Figure 15: tRA Treatment of 1205LU and MEL-SK-5 Melanoma Cells  67 
Figure 16: Time Course of tRA Treatment of 1205LU Melanoma Cells  69 
Figure 17: Time Course of tRA Treatment of MEL-SK-5 Melanoma Cells  70 
Figure 18: Time Course of tRA Treatment of FGF-BP2  
transfected SW-13 Cells       72 
Figure 19: Dose Response of tRA Treatment of MEL-SK-5 Cells  73 
Figure 20: Biological Activity of in SW-13 FGF-BP2 transfected Cells. 75 
Figure 21: Models of FGF-BP2 Functions      90 
Table 1: Expression of FGF-BP1 in Human Tumors, 
Tissues, and Cell Lines      11 
Table 2: Source and Classification of the Cancer Cell Lines    25 
Table 3:  FGF-BP1 and FGF-BP2 mRNA Expression in Human Cell Lines  63 
 
 
Introduction                                                                                                                 1 
 
 
 
 
     1. INTRODUCTION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction                                                                                                                 2 
 
1.1 Cancer and Tumor Growth 
 
The pathogenesis of tumor growth results from the disregulation of the normal 
mechanisms for regular cellular homeostasis in the context of the larger multicellular 
organism. Indeed, neoplasia by its very definition refers to cellular growth heedless to 
the signals provided by other, non neoplastic cells that would normally maintain the 
balance of cellular proliferation and death. Hanahan and Weinberg suggest that the 
vast catalog of cancer cell genotypes is a manifestation of six essential alterations in 
cell physiology that collectively dictate malignant growth: self-sufficiency in growth 
signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of 
programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000) It is 
proposed that these physiological changes are novel capabilities acquired during 
tumor development and that they are shared in common by most and perhaps all types 
of human tumors. 
 
 
1.2 Tumor Angiogenesis and Metastasis 
 
Angiogenesis, as one of the six proposed essential changes that are predictive for 
tumor growth, has been a major focus in cancer research. It is understood that critical 
to the process of tumor growth and metastasis is the persistent growth of new blood 
vessels, or angiogenesis, where new capillaries are induced to sprout from existing 
blood vessels. Angiogenesis is an early event in tumor formation and is often first 
detected during the preneoplastic stages of a tumor (reviewed by Hanahan and 
Folkman, 1996). The importance of angiogenesis for the growth of a tumor is 
reflected by the observation that most solid tumors are unable to grow beyond a 
microscopic size, no larger than about 2mm in diameter without a sufficient 
vasculature. Because angiogenesis is essential for tumor survival, an understanding of 
the mechanisms controlling new blood vessel formation have become a major focus 
of cancer research. In addition to the nourishing function of tumor blood vessels, they 
provide a route by which tumor cells metastasize to distant organs, metabolic waste is 
removed and, importantly, they supply growth factors to tumor cells. 
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Figure 1: Acquired Capabilities of Cancer 
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Figure 1: Acquired Capabilities of Cancer. The six essential alterations in cell homeostasis 
that are proposed to dictate malignant growth and to be shared by most of human tumors. 
(Adapted from Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 
100, 57-70) 
 
 
This doctrine is based on countless experiments using various tumor models and 
animal species (Folkman, and Shing, 1992; Folkman, 1991; Liotta, L.A. et al., 1991; 
Folkman and Klagsbrun, 1987; Cross and Dexter, 1991; Folkman, 1986; Fidler and 
Ellis, 1994). 
Consequently, the amount of angiogenesis in a primary tumor, as measured by 
microvessel density, appears to be directly related to the rate of metastasis of many 
solid tumors. A direct correlation between blood vessel density in primary tumors and 
their metastasis has been reported for many different tumor types including breast  
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cancer (Horak et al., 1992; Weidner et al., 1991; Bosari et al., 1992; Weidner et al., 
1992; Toi et al. 1993), lung cancer (Macchiarini et al., 1992), and squamous cell 
carcinoma of the head and neck (Gasparini et al., 1993). In these studies, the level of 
tumor angiogenesis was an independent prognostic indicator of the outcome of the 
disease. 
In the adult, new blood vessel formation occurs primarily during highly regulated 
processes such as the female reproductive cycle. The induction of angiogenesis also 
occurs in certain pathological situations, including wound healing, diabetic 
retinopathy and tumor formation. Neoangiogenesis is a highly regulated process 
where quiescent endothelial cells are induced to degrade the extracellular matrix and 
basement membrane, migrate into the interstitial space, proliferate and organize tube-
like structures. This process is mediated through a balance of both positive and 
negative angiogenic factors, the levels of which govern whether angiogenesis will be 
activated or inhibited (Hanahan and Folkman, 1996). With respect to positive 
angiogenic factors, more than a dozen distinct protein products are currently known to 
induce proliferation and migration of endothelial cells in vitro and/or angiogenesis in 
vivo, including Acidic Fibroblast Growth Factor (aFGF, FGF-1) und Basic Fibroblast 
Growth Factor (bFGF, FGF-2) (Christofori, 1997; Baird and Klagesbrun, 1991), 
Vascular Endothelial Cell Growth Factor (VEGF) (Kim et al., 1993), Hepatocyte 
Growth Factor (HGF) (Weidner et al., 1993), Epidermal Growth Factor (EGF) and 
Transforming Growth Factor Alpha (TGFα) (Schreiber et al., 1986) and Pleiotrophin 
(PTN) (Fang et al., 1992). 
In contrast, angiogenic inhibitors such as Angiostatin (O’Reilly et al., 1994; O’Reilly 
et al., 1996), Endostatin (O’Reilly et al., 1997), Thrombospondin-1, Interleukin-1 and 
Protease inhibitors serve to counter the effects of angiogenic activators and keep the 
vasculature in a quiescent state. The regular turnover time of endothelial cells in adult 
tissue is measured in years.  
Angiogenic factors, however, can induce endothelial cells to proliferate as fast as 
bone marrow cells, with resultant turnover times of only days. The ability of a tumor 
to shift the angiogenic balance in favor of angiogenic activators and turn on the 
‘angiogenic switch’ provides the tumor with a survival advantage by recruiting new 
blood vessels from the surrounding vasculature. 
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1.3 The Role of Fibroblast Growth Factors (FGFs) and a Binding Protein  
for FGF (FGF-BP1) 
 
Some of the most effective and best-studied angiogenic factors are members of the 
Fibroblast Growth Factor (FGF) family of polypeptides (Baird and Klagesbrun, 1991; 
Gospodarowicz et al., 1987). The FGFs are a family of at least 21 distinct growth 
factors which can interact with their membrane receptors coded for by four separate 
receptor genes and numerous protein products due to alternative splicing (reviewed in 
Schreiber et al., 1986; Powers C.J. et al., 2000). Members of the FGF family regulate 
various developmental processes and are potent stimulators of new blood vessel 
growth during wound healing and during tumor growth (Folkman and Klagsbrun, 
1987; Burgess et al., 1989; Baird et al., 1990). FGF-1 (aFGF), FGF-2 (bFGF) and 
FGF-4 (K-FGF) have all been shown to be angiogenic activators (Burgess et al., 
1989) and have therefore been a major focus of research in tumor vascularisation.  
aFGF and bFGF are widely expressed in normal tissues and in tumors of different 
origin, although not at elevated levels (Burgess et al., 1989; Moscatelli et al. 1986). 
The observation that aFGF and bFGF are expressed in normal tissues, which are not 
undergoing proliferation or angiogenesis, suggests that mechanisms other than their 
expression exist which regulate FGF activation. Unlike other members of the FGF-
family, aFGF and bFGF do not contain a signal sequence and are not secreted into the 
media in a classical way (Burgess et al., 1989; Mason, 1994). In fact, these growth 
factors are deposited into the extracellular matrix (ECM) where they are found tightly 
bound to membrane-attached heparansulfate proteoglycans. The immobilization of 
FGFs in the ECM quenches their biological activities by preventing them from 
reaching their high affinity receptors in the endothelial cell membrane (Vlodavsky et 
al., 1987; Rogelj et al., 1989; Saksela et al., 1988; Kiefer et al., 1990). 
There are several possible mechanisms by which bFGF can be released from its 
matrix storage site and thus activated. One established mechanism is the proteolytic 
degradation of the matrix by heparanases (Vlodavsky et al., 1988; Bashkin et al., 
1989; Moscatelli et al. 1992; Vlodavsky et al., 1991). Alternatively, active bFGF can 
be delivered from its ECM storage site to its receptors by an FGF binding protein, 
FGF-BP1.  
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1.4 FGF-BP1 is a Carrier for immobilized FGFs 
 
FGF-BP1 is a secreted, heparin-binding protein of 17 kD molecular mass that was 
originally isolated from A431 human epidermoid carcinoma cells (Wu et al., 1991). 
FGF-BP1 binds to aFGF and bFGF in a non-covalent reversible manner. Furthermore, 
bFGF bound to this protein is protected from degradation and retains its mitogenic 
activity (Wu et al., 1991). These characteristics indicate that FGF-BP1 could be an 
important regulator that releases immobilized FGFs from their matrix storage site and 
thus activates them in vivo (Czubayko et al., 1994; Rak and Kerbel, 1997).  
The role of FGF-BP1 in the activation of bFGF has been elucidated by several recent 
studies demonstrating the importance of this protein in regulating tumorigenesis and 
angiogenesis of several different tumor types. FGF-BP1 was transfected and 
overexpressed in a non-tumorigenic FGF-BP1 negative human adrenal carcinoma cell 
line (SW-13). Wild type SW-13 cells express bFGF but do not form colony in soft 
agar nor do they form tumors in athymic nude mice. The expression of FGF-BP1 in 
SW-13 cells resulted in a tumorigenic and angiogenic phenotype when these cells 
were injected into nude mice (Czubayko et al., 1994). It was also shown that these 
FGF-BP1 transfectants form colonies in soft agar and release the protein into their 
media together with bFGF in a non-covalently bound form. As expected, colony 
formation of FGF-BP1-transfected SW-13 cells can be blocked by a specific antibody 
for bFGF, demonstrating that the tumorgenic potential of FGF-BP is bFGF dependent 
(Czubayko et al., 1994). 
As an alternative approach, the impact of depleting endogenous levels of FGF-BP1 
with respect to its effect on angiogenesis and tumor growth was also investigated 
(Czubayko et al., 1997). In this study, FGF-BP1 positive cell lines ME-180 (human 
squamous cell carcinoma) and LS174T (human colon carcinoma) were transfected 
with ribozymes, which specifically target and degrade the endogenous FGF-BP1 
mRNA. Reduced FGF-BP1 expression resulted in decreased levels of biologically 
active bFGF released from the cells in culture. In addition, the growth and 
angiogenesis of xenografted ME-180 and LS174T tumors in mice was decreased in 
parallel with the ribozyme-mediated reduction of FGF-BP1. 
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Figure 2. Model of FGF-BP1 Function. 
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Figure 2. Model of FGF-BP1 Function. In some tumors, FGF-BP1 expression is 
upregulated (1) and FGF-BP1 is secreted (2) into the extracellular environment. (3) Secreted 
FGF-BP1 binds to immobilized bFGF, which is stored in the extracellular matrix. (4) bFGF is 
released in a soluble and bioactive form, (5) allowing it to reach its target cell receptor and 
stimulate angiogenesis. (From Rak, J. and Kerbel, R.S., Nature Med 3, 1083-1084, 1997). 
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Taken together, these studies point to a mechanism whereby FGF-BP1 expression 
facilitates the release of bFGF stored in the ECM, which then induces angiogenesis, 
as described in the model in Fig. 2 (Rak and Kerbel, 1997). According to this model, 
changes in the level of FGF-BP1 expression can shift the angiogenic balance in favor 
of bFGF activation and an angiogenic phenotype, suggesting that some human tumors 
can utilize FGF-BP1 as an ‘angiogenic switch molecule’.  
 
 
1.5 A novel secreted Protein with Similarities to FGF- BP1 
 
Recently a human cDNA clone containing an open reading frame (ORF) for a protein, 
which has amino acid sequence similarity of 21% to FGF-BP1 and a homology of 
41 % was discovered by a gene data bank blast search. No further significant 
homology was found with other known proteins. This certain gene sequence is located 
22kb 5’ upstream of the FGF-BP1 transcription start site on the short arm of human 
chromosome 4. It was derived from a BAC clone for human chromosome 4 whose 
genome sequencing is in progress. 
Data on the protein, derived from this gene were exclusively published by Ogawa et 
al.(Ogawa et al., 2001) In this publication the protein is referred to as ‘killer-specific 
secretory protein of 37 kDa’(Ksp37). Ksp37 is identified as a human Th1-specific 
protein, its expression being limited peripheral blood leukocytes, namely in Th1-type 
CD4+ T cells, effector CD8+ T cells, γδ T cells and CD16+ NK cells.  
Ogawa et al. show a deduced amino acid sequence that displays a 24% identity to 
FGF-BP1. They describe a related conformation of the two proteins, concerning the 
positioning of eight cysteine residues in the signal-truncated form of Ksp37 that are 
completely conserved in FGF-BP1. They also state that calculated isoelectric points, 
which are 9.15 for Ksp37 and 9.28 for FGF-BP1 and hydrophobicity profiles are very 
similar to each other. From these data they suggest that like FGF-BP1, Ksp37 could 
bind to proteins to regulate their activity and thereby mediate in a yet unknown 
function. 
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These data led to the question if this protein has also functional similarity to FGF-
BP1. Consequently in the further investigation this novel molecule was named FGF-
BP2. 
Ogawa et al. present further analysis of particular molecular characteristics of FGF-
BP2, which reveal that the deduced primary structure of FGF-BP2 shows nine 
potential O-glycosylation sites as analyzed by the NetOGlyc program, but no possible 
N-glycosylation site. The protein was examined by hydropathy blot analysis, 
revealing two strongly hydrophobic regions at both termini. It is described that the 
amino-terminal hydrophobic region of the protein has a characteristic secretory 
sequence with a predicted cleavage site after the glycine of amino acid position 19. 
This implies that the carboxyl-terminal hydrophobic region, which consists of 14 
amino acids, would seem too short to serve as a transmembrane domain. Ogawa et al. 
suggest from these findings, that FGF-BP2 might be secreted. Indeed, they show that 
pCMV/T48 transfected COS-7 cells secrete FGF-BP2 as a 37-kDa form, while they 
retain a 28-kDa species and a 37-kDa form. Also Th-1 cells secrete FGF-BP2 in as a 
37-kDa form. From these results it is implied that FGF-BP2 is synthesized as a 
polypeptide with an apparent molecular mass of 28kDa, then modified, possibly by O-
glycosylation, and secreted into the extracellular space as a 37-kDa form. 
FGF-BP2 was detected in normal human sera and, consistent with differences in the 
absolute counts of blood T and NK cells between children and adults, the serum FGF-
BP2 levels were significantly higher in children than in adults. It was shown that in 
patients with infectious mononucleosis, transient elevation of serum FGF-BP2 
concentrations were detected during the early acute phase of primary EBV infection. 
It is postulated that FGF-BP2 must be involved essentially in the process of cytotoxic 
lymphocyte mediated immunity. Ogawa et al. state that FGF-BP2 did not show direct 
association with 125I-labeled recombinant human basic FGF and no effect on the 
exogenous bFGF-dependent or the spontaneous colony growth of SW-13 cells in soft 
agar.  
For further exploration of this protein with regard to functions potentially similar to 
FGF-BP1, one of the first steps is the analysis of its expression profile outside of Th-1 
cells, namely in tumor cell lines. It therefore is beneficial to review the expression of 
FGF-BP1 in normal and neoplastic tissues, to facilitate a comparison of the 
expression patterns of both FGF-binding proteins. 
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1.6 FGF-BP1 Expression in Normal and Neoplastic Tissues 
 
The expression pattern of FGF-BP1 in both normal and neoplastic cells has revealed 
that the expression of this protein is highly regulated and tissue-specific. The 
screening of FGF-BP mRNA expression in normal human adult and fetal tissues 
demonstrated that FGF-BP1 expression is highest in the trachea, colon, uterus and 
lung (Table 1) (Tuveson, 1998). Notably from these studies, FGF-BP1 mRNA 
expression is generally positive in the intestinal lining epithelia, particularly in the 
aerodigestive (trachea, lung, stomach, small intestine, appendix, colon, etc.) and 
genitourinary (uterus, bladder, prostate, kidney) systems. The observation that all 
screened neuroectodermal-derived tissues were negative for FGF-BP1 (Table 1) 
(Tuveson, 1998) is also noteworthy. 
FGF-BP1 expression is also restricted to certain types of cell lines and primary 
tumors. A screening of different human tumor cell lines showed that FGF-BP1 
mRNA was positive in most squamous cell carcinoma (SCC) cell lines derived from 
different origins including lung, bladder, skin, and cervix (Table1) (Czubayko et al. 
1994). FGF-BP1 expression was also highly positive in clinical samples of primary 
and metastatic head and neck SCC (Czubayko et al. 1994). FGF-BP1 was also 
expressed in colonic adenocarcinoma cell lines and in tumor samples from colon 
cancer patients (45), as well as in breast carcinoma cell lines and tumor tissues. Most 
other cell lines of epithelial or mesenchymal origin did not show any detectable FGF-
BP1 mRNA expression. The overall expression pattern of FGF-BP1 suggests a role 
for this growth factor as activator in the SCC as well as in colon cancer and breast 
cancer. The functional significance of FGF-BP1 expression in colon cancer has been 
demonstrated and discussed elsewhere (Tuveson, 1998). 
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Table 1: Expression of FGF-BP1 in Human Tissue, Tumors and Cell Lines. 
 
 
FGF-BP1 Positive FGF-BP1 Negative 
Normal Tissue Fetal skin                   Spleen 
Trachea                      Uterus 
Lung                          Bladder 
Colon                         Kidney 
Stomach                     Prostate 
Small intestine           Testis 
Appendix                   Ovary 
Salivary gland            Placenta 
Lymph node               Mammary gland 
Thymus 
Brain 
Bone marrow 
Heart  
Tumor Tissue Head and neck SCC 
Colon adenocarcinoma 
Breast carcinoma (lobular and ductal) 
 
Tumor Cell Lines Keratinocytes: 
         Primary (HKc), 
         Immortalized (HFK-SV40,  
                                 HFK-VP16) 
SCC: 
         Lung (SW900, NCI-H520, NCI- 
                    H596) 
         Bladder (SCaBER) 
         Pharynx (FaDu) 
         Cervix (ME-180, SiHa, HeLa) 
         Epidermoid (A431, A253) 
         Tongue (SCC-25) 
         Buccal mucosa (SqCC/Y1) 
Colon adenocarcinoma: 
         (LS174T, LoVo, Sk-Co1, LS180) 
Breast carcinoma: 
         (MDA-MB-231, BT549, T47D, 
          MDA-MB-468, MCF/ADr, 
          MDA-MB-445) 
 
Fibroblasts: 
(NIH3T3) 
Adrenal carcinoma: 
(SW-13) 
Osteosarcoma: 
(HOS, MNNG/HOS, 
MG-63) 
Glioblastoma: 
(T98G) 
Astrocytoma: 
(U87, SW1088) 
Hepatocellular 
carcinoma: 
(HepG2) 
Liver 
adenocarcinoma: 
(SK-HEP-1) 
 
 
Table 1: Expression of FGF-BP1 in Human Tumors, Tissues, and Cell Lines. The 
distinctive expression pattern of FGF-BP1 mRNA in human tumors, tissues, and cell lines. 
(Czubayko et al., 1994;Tueveson, 1998) 
 
 
 
 
 
Introduction                                                                                                                 12 
 
1.7 Mouse FGF-BP1 and its Regulation during Embryonic Development  
and Skin Carcinogenesis 
 
In order to compare the two FGF-BP genes it is important to consider the mouse FGF-
BP1 and its role in skin carcinogenesis. since new data presented here will show a 
certain significance of FGF-BP2 in this process.  
Using sequence information from the human FGF-BP1 cDNA the mouse FGF-BP1 
gene was previously isolated by screening a mouse genomic library (Kurtz et al., 
1997). The overall nucleotide sequence homology between the mouse and the human 
cDNA sequences is 68%, and shows no homology with other sequences in genbank or 
other databases. The mouse FGF-BP1 cDNA predicts a 251 amino-acid protein that 
shows 63% identity and 74% similarity with the amino-acid sequence of the human 
FGF-BP1 protein. The high homology between the mouse and human suggests a high 
selection pressure on the function of this protein. The mouse and human also share 
similar charge and hydrophobic character. Furthermore, like the human protein, 
mouse FGF-BP1 is able to non-covalently bind bFGF and stimulate soft agar colony 
formation when expressed in SW-13 cells (Kurtz et al., 1997) 
Similar to the human, expression of the mouse FGF-BP1 in the adult is highly tissue-
specific, with high levels in the lung and placenta and somewhat lower levels in the 
intestine, skin and ovaries (Kurtz et al., 1997). Furthermore, mouse FGF-BP1 
expression is also highly regulated during mouse embryonic development. In situ 
analysis of mouse FGF-BP1 mRNA in embryonic tissues showed that expression 
during all stages of development was highly restricted to the skin, lungs and intestine, 
with a continuous increase during development, which peaked perinatally and 
dropped significantly in the adult. In the skin, FGF-BP1 was found in the basal and 
suprabasal cell layers and hair follicles and expression increased in association with 
the development of the skin layers. In the adult skin, when morphogenic changes are 
minimal, FGF-BP1 expression decreased dramatically. These studies demonstrate a 
strong correlation between FGF-BP1 expression and skin development where it 
presumably acts in a paracrine manner by mobilizing bFGF stored in the dermal layer 
of the skin where it plays an inductive role in skin development (du Cros, 1993). 
Due to the fact that FGF-BP1 is expressed in a variety of SCCs, in normal human 
keratinocytes, and in the mouse embryonic skin (Wu et al., 1991; Czubayko et al.,  
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1994; Kurtz et al., 1997; Vellucci et al., 1995), the role of FGF-BP1 during skin 
carcinogenesis was explored (Kurtz et al., 1997). The mouse model of skin 
carcinogenesis describes a predictable multistage process of tumor formation from the 
clonal expansion of a normal epidermal cell into a benign squamous papilloma, which 
progresses into a malignant squamous cell carcinoma (reviewed by Yuspa, 1994). In 
this experimental protocol, a carcinogen induced mutational event is generated 
through the topical application of DMBA (7,12-dimethylbenz(a)anthracene) to the 
mouse skin, leading to an initiation event in the cell where altered response to signals 
for growth and differentiation result in a selective growth advantage. The mouse skin 
is subsequently treated with repeated applications of a tumor promoter, such as the 
phorbol ester TPA (12-O-tetradecanoyl phorbol 13-Acetat), causing a selective clonal 
outgrowth of initiated cells into multiple squamous cell papillomas. Finally, 
conversion of a papilloma to a malignant carcinoma in this model is generally a 
spontaneous process, involving a number of genetic and epigenetic aberrations.  
 
 
Figure 3: Mouse model of skin carcinogenesis. 
STAGE: Initiation          Promotion                 Progression and malignant Conversion
TREATMENT: DMBA            TPA                                       spontaneous
BIOCHEMICAL    rasHA                   PKC                                             Trisomy 6,7
ALTERATION:     mutation          activation                                    TGFβ
p53 mutation
rasHa-mut homozygous
Integrin expression
NORMAL PAPILLOMA CARCINOMA
 
Figure 3: Mouse Model of Skin Carcinogenesis. Multi-stage process of skin carcinogenesis 
as described through experimental treatment with DMBA/TPA. (Adapted from Yuspa, S., 
Cancer Res 54, 1178-1189, 1994). 
 
 
 
Introduction                                                                                                                 14 
 
Experimental skin carcinogenesis in the mouse, as shown in Fig 2, provides an 
insightful model for the molecular analysis of multistage carcinogenesis of other 
epithelial cancers, including other SCCs and also colon cancer (Kinzler and 
Vogelstein, 1996). 
Using this as a model, the role of FGF-BP1 expression during tumor progression was 
investigated. In DMBA/TPA-induced papillomas, levels of FGF-BP1 mRNA were 4-
5 fold higher than in untreated skin and remained upregulated after malignant 
conversion into SCC (Kurtz et al., 1997). Moreover, FGF-BP1 mRNA was 
upregulated in cell lines derived from DMBA/TPA-induced papillomas and a cell line 
derived from DMBA-initiated skin and selected for resistance to Ca2+-induced 
terminal differentiation (Kurtz et al., 1997). These studies demonstrated a potential 
function of FGF-BP1 during the early, premalignant stages of skin tumorigenesis, 
which coincides with the activation of angiogenesis as an early and necessary event in 
tumor formation. 
The role of FGF-BP1 in the formation of human skin SCC was also examined using a 
similar model to the mouse, where human skin was xenografted onto SCID mice and 
treated with the DMBA/TPA carcinogen protocol. Similar to the mouse, human FGF-
BP1 protein was dramatically upregulated upon carcinogen treatment compared to 
untreated human skin (Aigner et al., in review). Interestingly, the upregulation of 
FGF-BP2 was already detectable even before the histological neoplastic change was 
visible. Furthermore, FGF-BP1 upregulation was paralleled with an increase in 
microvessel density and positive p53 staining, which is indicative of the onset of 
carcinogenesis. Both in the mouse as well as in the human, FGF-BP1 is associated 
with the early neoplastic stages of skin SCC, a stage where angiogenesis is thought to 
play a critical role. 
 
 
1.8 Regulation of FGF-BP1 by Fetal Bovine Serum, EGF and TPA 
 
Fetal Bovine Serum (FBS) and mitogens such as Epidermal Growth Factor (EGF) and 
12-O-tetradecanoyl phorbol 13-Acetat (TPA) are known to be inductive for the FGF-
BP1 mRNA expression as to be determined by Northern blotting analysis. 
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It was shown that FGF-BP1 mRNA is upregulated in its gene expression by treatment 
with fetal bovine serum (FBS) (Harris et al., 2001). Treatment of serum starved ME-
180 cells with FBS results in a rapid increase in steady-state levels of FGF-BP1 
mRNA and in the rate of FGF-BP1 gene transcription. A time-dependence of FGF-
BP1 mRNA induction by serum and EGF was shown. Treatment of serum-starved 
ME-180 cells with 10% FBS resulted in a rapid and transient increase in FGF-BP1 
mRNA, which peaked after 6 h. This time course of serum induction is very similar to 
the induction mediated by EGF (Harris et al., 2000a, Harris et al., 2000b). Also the 
upregulation of FGF-BP1 gene expression by TPA, which was described earlier 
(Harris et al., 1998) revealed a similar time course. 
From the rapid (within 1h) induction of FGF-BP1 mRNA by serum a direct 
transcriptional mechanism of activation was suggested and proved by nuclear run on 
analysis and a transcriptional inhibition of the FGF-BP1 expression by actinomycin D 
whereas in contrast inhibition of de novo protein synthesis with cycloheximide did not 
block the serum effect. Because both EGF and serum treatment increase FGF-BP 
mRNA with similar kinetics, it was questioned whether the serum effect was 
dependent on the EGF receptor. It was shown that this is not the case but that the 
serum induction of FGF-BP1 must be mediated through an alternate receptor 
pathway(s). The activation of these pathways together has no additive or synergistic 
effect on the gene expression of FGF-BP1. Treatment of ME-180 cells with EGF or 
FBS in combination caused a maximal fourfold induction. Combined treatment with 
EGF and FBS did not induce FGF-BP1 mRNA higher than fourfold. 
Phorbol esters, such as TPA, are potent tumor promoters as pharmacological 
activators of the protein kinase C (PKC) pathway (Blumberg, 1988). Many of the 
PKC enzyme family members play an important role in cell growth and 
differentiation for different cell types, including a well-characterized regulation 
during normal keratinocyte differentiation (Stabel and Parker, 1991; Nishizuka, 1992; 
Dlugosz, 1995). PKC activation by TPA or growth factors has pleiotrophic effects. 
During neoplastic transformation, PKC activation is often a central and critical event 
in the early stages of tumor promotion, as seen in the model of epidermal 
carcinogenesis. 
Recent studies demonstrated that FGF-BP1 is upregulated during DMBA/TPA 
treatment of both mouse and human skin (Kuetz et al., 1997; Aigner et al., submitted).  
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This observation led to the hypothesis that FGF-BP1 may be regulated directly by 
TPA activation of PKC in human squamous cell carcinoma, where FGF-BP1 is 
commonly overexpressed. Upon TPA treatment of ME-180 cells, FGF-BP1 mRNA 
amounts (as determined by Northern Blot analysis) increased in a time- and dose-
dependent manner (Harris et al., 1998). 
 
 
1.9. Regulation of FGF-BP1 by Retinoids 
 
Former studies revealed a well-defined in vitro regulation of FGF-BP1 expression by 
all-trans retinoic acid (tRA). Vitamin A (retinol) and its derivatives (retinoids) are 
necessary for normal growth and development of vertebrates. Experimental models of 
carcinogenesis have demonstrated that retinoids can suppress carcinogenesis in 
various epithelial tissues, such as the oral cavity, bladder, lung, prostate and 
mammary gland (Bertram et al., 1987; Lotan, 1994), as well as directly inhibit the 
effects of tumor promotion during skin carcinogenesis (Moon et al., 1994; De Luca et 
al., 1994). More importantly, clinical trials have indicated that retinoids are useful as 
cancer chemopreventive agents for SCC of the upper aerodigestive tract, skin and 
cervix, as well as cancers of the breast and ovaries (Hong and Itri, 1994; Lippman et 
al., 1995; De Palo et al., 1995; Lotan, 1996). 
Retinoids have been shown to inhibit the growth and reverse aberrant differentiation 
of SCC cells in vitro, as shown by changes in expression of squamous differentiation 
markers (Lotan, 1994). Other studies have shown that retinoids markedly inhibit 
angiogenesis in the chorioallantoic membrane model (Oikawa et al., 1989) and in an 
experimental in vivo model of cutaneous angiogenesis in the mouse (Majewski et al., 
1993; Majewski et al., 1994). 
The mechanism by which retinoids can act to inhibit angiogenesis is currently 
unknown, although it is likely that retinoids affect multiple targets along the 
angiogenic process. One target by which retinoids may act to inhibit angiogenesis is 
the transcriptional inhibition of matrix degrading proteins, such as collagenase or 
stromelysin, which are required for the matrix remodeling that coincides with new 
blood vessel formation (Brinckerhoff et al., 1984; Quinones et al., 1989). In addition, 
retinoids may decrease levels of angiogenic activators, resulting in a shift in the  
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angiogenic balance in favor of inhibition. Classical angiogenic factors, however, such 
as FGFs or VEGF, are not known to be regulated by retinoids.  
FGF-BP1, however, has been found to be a target for downregulation by retinoids. It 
was demonstrated that in six different human SCC cell lines FGF-BP1 mRNA is 
down-regulated by 39-89% within 24 hours (Liaudet-Coopman et al., 1996). In the 
ME-180 cell line it was shown that tRA down-regulates FGF-BP1 mRNA in a time- 
and dose- dependent manner. The maximum effect was reached 8-12 h after tRA 
exposure in a concentration of 10-5 M. Since tRA massively decreases the FGF-BP1 
mRNA half life from >16 hours to 5 hours and also decreases gene transcription by 2- 
to 3-fold within 1hour it was suggested that the down-regulation of FGF-BP1 mRNA 
is achieved through a combination of transcriptional and posttranscriptional 
mechanisms (Liaudet-Coopman et al., 1996). Furthermore, it was demonstrated that in 
vivo tRA treatment of SCC xenografts in athymic nude mice reduces FGF-BP1 
mRNA expression, correlating with inhibition of angiogenesis, induction of apoptosis 
and a decrease in tumor growth rate (Liaudet-Coopman et al., 1997). These results 
indicate that the tRA-induced downregulation of FGF-BP1 contributes to the 
reduction of angiogenesis in SCC, presumably due to the inability of FGF to become 
activated. Further studies will have to answer the question if this regulation also 
applies to FGF-BP2. 
Most of the actions of retinoids are mediated through high affinity nuclear retinoic 
acid receptors (RARs) and retinoic ‘X’ receptors (RXRs) (reviewed by Chambon, 
1996; Mangelsgorf and Evans, 1995). Several of the human epidermal keratin genes 
have been shown to be transcriptionally downregulated by retinoids through RAR 
binding in their promoter regions (Tomic et al., 1990; Stellmach et al., 1991; Tomic-
Camic et al., 1992; Tomic-Camic et al., 1996). Also the downregulation of the 
stromelysin and of the collagenase genes by retinoids is mediated through binding 
sites in their respective promoters (Nicholson et al., 1990; Lafyatis et al. 1990; Kamei 
et al., 1996). It seems likely that many of the therapeutic effects of retinoids are 
related to its RAR-mediated competing inhibition of transcription factor activity. In 
that respect, several synthetic retinoids have been found which transrepress as 
efficiently as retinoic acid, but are totally ineffective for transactivation (Chen et al., 
1995; Fanjul et al., 1994; Nagpal et al., 1995). Such “dissociated” synthetic retinoids 
promise to be interesting candidates for further drug design.  
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2.10 The objective of this study 
 
FGF-BP2 is a new interesting candidate with potential similar functions 
to FGF-BP1 
 
One can hypothesize that in addition to structural homologies, FGF-BP2 also displays 
functional analogies to FGF-BP1. Therefore the expression profile of FGF-BP2 in 
human tissues and tumor cell lines was analyzed by Northern blotting, and serum, 
TPA, EGF or retinoid-mediated regulation of FGF-BP2 expression was analyzed. 
Finally, the tumorigenic potential was determined by FGF-BP2 overexpression. 
 
 
Specific Tasks: 
 
1. Cloning the FGF-BP2 cDNA 
2. Construction of FGF-BP2 expression vector 
3. Screening tissues and various tumor cell lines for FGF-BP2 expression 
4. Comparison of the expression patterns of FGF-BP1 and FGF-BP2 
5. Analyzing FGF-BP2 regulation in two melanoma cell lines under 
treatment with drugs and growth factors 
6. Transfecting the FGF-BP2 cDNA for overexpression 
7. Performing a soft agar assay with FGF-BP2 transfected cells 
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2.1 Chemicals 
 
Agarose, Electrophoreses Grade  Ultra Pure, Life Technologies, USA 
Ampicillin (aminobenzylpenicillin)  USB, USA  
Chloroform      EM Science, USA 
DEPC       Quality Biological Inc., USA 
DMSO       Mallinckrodt AR ®, USA 
Ethidium bromide     Oncor, USA 
Ethanol      SIGMA, USA 
Formaldehyde (37 % v/v Solution)   SIGMA, USA 
Formamide      Boehringer Mannheim Corp., USA 
Isopropanol      Fischer Scientific, USA 
SDS        SIGMA, USA  
Sodium Chloride     Fischer Scientific, USA 
Sodium Citrate     EM Science, USA  
EDTA        Biofluids, Inc., USA 
Tryptone      Difco Laboratories, USA 
Yeast Extract      Difco Laboratories, USA 
Tris-Base      Life Technologies, USA 
Boric Acid      SIGMA, USA 
Geniticin® (G418 Sulphate)    Life Technologies, USA 
Glycerol      SIGMA, USA 
Bromphenol Blue     Fischer Scientific, USA 
Bacto-Agar      Difco Laboratories, USA 
BSA       SIGMA, USA 
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2.2 Working Material and Apparatus 
 
MicroSpin™ S-200 HR columns   Amersham, UK 
Ultracentrifuge Sorvall RC-5B   Du Pont Instruments, USA 
Centrifuge tubes     Seton, USA 
Speedvac concentrator    Savant, USA 
Hybridization oven     Hybaid, Labnet, USA 
Liquid scintillation counter 1209   Rackbeta Pharmacia, USA 
DNA gel apparatus     OWL Scientific, USA 
RNA gel apparatus     OWL Scientific, USA 
Spectrophotometer     Pharmacia, USA 
PCR machine Robocycler 40    Stratagene, USA 
Image analyzer Eagle Eye II    Stratagene, USA 
UV light box       Fischer Scientific, USA 
Micro centrifuge 5415 C    Eppendorf, USA 
Nitrocellulose membrane    Micron Separations Inc., USA 
Whatman paper     Whatman International, Ltd., USA 
Parafilm      American National Can TM ,USA 
Gel electrophoresis camera OSP   IBI, USA 
Incubator Shaker Innova 4000   New Brunswick Scientific, USA 
Heat Blocks      Fischer Scientific, USA 
UV Stratalinker 1800     Stratagene, USA 
Electrophoresis power source EPS 600  Pharmacia, USA 
Phosphor Imager 445 SI    Molecular Dynamics,USA 
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2.3 Enzymes 
 
Restriction  Concentration Reaction Source 
Endonucleases    Buffer 
 
BamH I  20 U/µl  NEBuffer 2 New England Biolabs Inc 
Xba I   20 U/µl  NEBuffer 2 New England Biolabs Inc. 
Hind III  20 U/µl  NEBuffer 2 New England Biolabs Inc. 
 
 
2.4 Molecular Weight Standards 
 
1 kb DNA ladder     Life Technologies, USA 
 
 
2.5 Vectors 
 
pCR® 3.1  (5.0 kb)     Invitrogen®, USA 
pcDNA3.1/Myc-His  (5.5 kb)    Invitrogen®, USA 
 
 
2.6 cDNA Probes for Nothern Blot Analysis 
 
GAPDH - cDNA     Clontech (1.1 kb) 
FGF-BP 2 ORF cDNA    BamH I/Xba I Fragment  
       (700 bp) isolated from 
       pCR ® 3.1 /FGF-BP2 Vector  
FGF-BP1 cDNA        Dr. Violaine K. Harris, 
       Lombardi Cancer Center 
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2.7 Molecular Biology Reagents 
 
Salmon Sperm DNA     Life Technologies. USA 
T4 DNA Ligase     Invitrogen®, USA 
10x Ligation Buffer     Invitrogen®, USA 
 
 
2.8 Kits and Reagents 
 
RNA Stat-60      TEL-TEST Inc., USA 
QIAEX II Gel Extraction Kit (150)   Qiagen Inc., USA  
Qiagen Plasmid Midi/ Maxi Kit   Qiagen Inc., USA 
Rediprime ™ II random prime labeling system Amersham, UK  
Scintillation Fluid Bio-Safe II ™   RPI Corp., USA 
LIPOFECTAMINE™      Life Technologies, USA 
 
 
2.9 Radioisotopes 
 
Radioisotope  Half life Specific  Concentration        Source 
      (t ½)  Activity 
 
α-(32P) dCTP  14.3 days 6000 Ci/mmol      10 µCi/µl          Amersham, USA 
 
 
2.10 Bacterial Cells 
 
Escherichia coli DH5α    Life Technologies, USA 
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2.11 Bacterial Growth Media and Plates 
 
LB Medium      1 % (w/v) Tryptone 
     0.5 % (w/v) Yeast extract 
     1 % (w/v) NaCl 
     pH adjusted to 7.5 
 
LB Plates with Ampicillin    LB medium  
1.5 % (w/v) Bacto-Agar 
Ampicillin 50 µg/ml  
 
 
2.12 Cell Culture Materials 
 
IMEM       Biofluids, Inc., USA 
Leibovitz’s L15 Medium    Life Technologies, USA 
OPTI–MEM® I Reduced Serum Medium  Life Technologies, USA 
Keratinocyte-SF Medium    Life Technologies, USA 
Fetal Bovine Serum     Life Technologies, USA 
Trypsin/EDTA     Life Technologies, USA 
Cell Culture Freezing Medium 
with DMSO      Life Technologies, USA 
Cell Culture Flasks (Vent, 75 & 162 cm2)  Costar, USA 
Cell Scraper      Costar, USA 
Bottle Filter System     Corning, Inc., USA 
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2.13 Mammalian Cell Lines 
 
Table 2: Source and Classification of the Cancer Cell Lines 
Cell Type Cell Line Source 
Melanoma 1205LU 
 
SK- MEL- 5 
SK- MEL- 24 
SK- MEL- 31 
Dr. M. Herlyn, Wistar  
Institute, Philadelphia 
ATCC (HTB 70) 
ATCC (HTB 71) 
ATCC (HTB 73) 
Prostate Carcinoma LNCaP- FGC- 10 
DU 145 
PC-3 
ATCC (CRL 1740) 
ATCC (HTB 81) 
ATCC (CRL 1435) 
Colon Carcinoma COLO 357 
 
LS 180  
HT-29 
SW 480 
SW 680 
Dr. H. Juhl, 
Lombardi Cancer Center, 
Washington, DC 
ATCC (CL 187) 
ATCC (HTB 38) 
ATCC (CCL 228) 
Lombardi Cancer Center 
Tissue Culture Core Facility 
Breast Carcinoma  BT- 20  
BT- 549  
MCF- 7  
MDA- 231 
MDA- 435  
SK- BR- 3 
MDA- 468  
MDA- 460 
ATCC (HTB 19) 
ATCC (HTB 122) 
ATCC (HTB 22) 
ATCC (HTB 26) 
ATCC (HTB 129) 
ATCC (HTB 30) 
ATCC (HTB 132) 
Lombardi Cancer Center 
Tissue Culture Core Facility
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Cell Type Cell Line Source 
Adrenal Carcinoma SW-13  ATCC (CCL105) 
Cervical Carcinoma ME-180 ATCC (HTB 33) 
Choriocarcinoma JAR 
JEG- 3  
ATCC (HTB 144) 
ATCC (HTB 36) 
Pancreatic Carcinoma PANC- 89 Lombardi Cancer Center 
Tissue Culture Core Facility
Leukemia HL-60  
 
Jurkat 
K-562  
Lombardi Cancer Center 
Tissue Culture Core Facility 
ATCC (CRL 8163) 
ATCC (CCL 243) 
Hepatocellular carcinoma Hep G2 ATCC (HB8065) 
Glioblastoma  U-87 
U-138  
U-373 
T-98  
 
A-172  
Hs 683  
ATCC (HTB 14) 
ATCC (HTB 16) 
ATCC (HTB 17) 
Lombardi Cancer Center 
Tissue Culture Core Facility 
ATCC (CRL 1620) 
ATCC (HTB 138) 
Other  WI-38 (Lung)  
HU-VEC        
(Human umbilical vein 
 endothelial cells) 
ATCC (CCL 75) 
ATCC (CRL 1730) 
Neonatal melanocytes  Lombardi Cancer Center 
Tissue Culture Core Facility
 
 
Table 2: Source and Classification of the Cancer Cell Lines. All cell lines that were screened 
for FGF-BP2 expression are listed for their type and origin. 
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2.14 Buffers and Solutions 
 
10 x TBE      1 M Tris-Base 
0.8 M Boric Acid 
20 mM EDTA 
 
10 x MOPS      Quality Biological, Inc., USA 
 
DNA Running Buffer     1 x TBE 
 
DNA Loading Buffer     0.1 mM          EDTA 
0.2 %    (w/v) SDS 
50%      (v/v) Glycerin 
0.005 % (v/v) Bromphenol Blue 
in 1 x TBE   
 
RNA Running Buffer      1 x MOPS 
       in DEPC-H2O 
 
RNA Loading Buffer     50 % (v/v)    Formamide 
       17.5 % (v/v) Formaldehyde 
       1 x               MOPS 
       10 % (v/v)    Bromphenol Blue 
       in DEPC- H2O 
 
50x Denhardt’s Buffer    2 % (w/v) Polyvinyl-Pyrrolidone 
       2 % (w/v) BSA 
       2 % (w/v) Ficoll  
 
20 x SSC      3 M Sodium Chloride 
       0.3 M Sodium Citrate 
DEPC-H2O      0.1 % (v/v) DEPC 
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2.15 Northern Blot Solutions 
 
Prehybridization Solution    50 % (v/v) Formamide 
       5 x             SSC 
1%   (w/v) SDS 
5 x             Denhardt’s Buffer 
100 µg/ml  Denatured salmon sperm 
DNA 
 
Washing Solutions     (1) 2 x SSC 
(2)       2 x SSC/1 % (w/v) SDS 
               (3) 0.1 x SSC 
 
Stripping Solution     0.1 x SSC 
 
 
2.16 Compounds for Cell Treatment 
 
12-O-tetradecanoyl phorbol 13-Acetat   SIGMA, USA 
(TPA), Solvent: 100% DMSO 
all-trans-retinoic acid, Solvent 100% DMSO            SIGMA, USA 
(tRA)        
human recombinant     Clonetics, USA 
Epidermal Growth Factor (EGF) 
human recombinant     Life Technologies, USA 
Basic Fibroblast Growth Factor (bFGF) 
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3.1 General Laboratory Techniques 
 
3.1.1 Sterilization of Solutions and Work Materials 
 
Solutions, tubes, glassware, plastics, deionized H2O and other items were sterilized by 
autoclaving for 45 min at 121o C 
 
3.1.2 Determination of DNA and RNA Concentrations 
 
A spectrophotometer was used to measure the concentration of nucleic acids in solutions. 
2µl of DNA or RNA samples were added to 98 µl sterile H2O (1:50 dilution) for an 
optical density (OD260nm ) reading. The DNA concentration was determined based on the 
fact that an absorption of 1 at 260nm is equivalent to a DNA concentration of 50µg/ml. 
Absorption (OD 260nm ) x 50 µg/ml x Dilution Factor (50) = µg/ml DNA. For RNA, an 
absorption of 1 at 260nm corresponds to an RNA concentration of 40 µg/ml. Absorption 
(OD 260nm  ) x 40 µg/ml x Dilution Factor (50) = µg/ml RNA. The purity of nucleic acid in 
solution can be determined by dividing the absorption’s (OD260/280 nm ), as peptides bonds 
absorb UV light at 280nm. Protein contaminated DNA or RNA solutions have a ratio  
of < 1.7. 
 
3.1.3 Work with RNA 
 
Precautions were used while isolating and handling RNA in order to prevent degradation. 
All used solutions, glassware and plastics were sterilized to ensure the absence of RNase, 
which is an extremely stable enzyme requiring no cofactors to exert its effect of RNA 
digestion and degradation. Everything was handled only while wearing gloves. 
Workbench, RNA gel apparatus, gel tray and gel combs were cleaned with RNaseZAP™ 
(RNase-Inhibitor). RNA was always dissolved in DEPC-H2O and stored at –80o C or on 
ice while handling. 
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3.1.4 Work with DNA 
 
Although DNA is by far not as sensitive to degradation as RNA it was also kept on ice 
while working with it and stored in a freezer at –20o C. 
 
3.1.5 Work with Radioactive Isotopes 
 
The only isotope used in this study was 32P, which was purchased as an incorporated 
component of the deoxyribonucleotide Cytosine Tri-Phosphate (dCTP). Radioactive 
phosphorous (32P) emits β-radiation and has a maximum principle emission of 1.709 
MeV. Radioactive nucleotides were kept in a safety container at –20o C and thawed 
behind a Plexiglas shield immediately before usage. All radioactive contaminated waste, 
liquid and solid, was disposed in special radioactive waste containers.  
 
3.1.6 Gel Electrophoresis of Nucleic Acids 
 
DNA Agarose Gel Electrophoresis 
 
1 % (w/v) agarose was added to100ml 1x TBE buffer and heated until the agarose was 
completely dissolved. Next, 5µg/ml ethidium bromide was added to the gel solution for 
DNA visualisation and the gel was poured into a gel tray. Before its polymerization (20 
min.) combs were placed in the gel to create wells. The DNA solutions (i.e. plasmid 
DNA or PCR product) were mixed with 20µl of DNA loading buffer and loaded in the 
wells. The DNA fragments were separated by electrophoresis in parallel to a 1 kb DNA 
ladder for 1-2 hours at 80-100 volts in DNA running buffer. DNA bands were detected 
under UV light in the image analyzer or on an UV light box. 
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RNA Formaldehyde Gel Electrophoresis 
 
1 % (w/v) agarose (1g according to a total volume of 100ml) was heated in 87 ml DEPC 
H2O until the agarose had completely dissolved. 10 ml 10x MOPS buffer were added to 
achieve a final dilution of 1x MOPS. This was followed by the addition of 3ml 
formaldehyde to make it a 3% solution and 5µg/ml ethidium bromide. The gel was 
poured under the chemical hood due to the toxicity of formaldehyde. Combs were stuck 
in the gel to form loading wells. Once the gel was polymerized it was allowed to set for 1 
hour in 1x MOPS buffer. The RNA, which was dissolved in 20 µl RNA loading buffer 
was denatured at 65o C for about 10 min and loaded into the wells. The RNA was 
separated at 60-80 volts for about 3 hours in RNA running buffer. Native RNA molecules 
exist in a folded confirmation as partially double stranded molecules which would 
interfere with their electrophoretic mobility as well as their accessibility to hybridization. 
To prevent this, the denaturing agent formaldehyde was used in the gel. 
 
3.1.7 Work with Bacteria 
 
Inoculation 
 
A streak of transformed (see section 3.2.4) bacterial cells taken from an overnight culture 
was spread onto a Bacterial Stam Plate to generate single colony growth. Bacteria were 
picked from a mother colony into 5ml LB medium, containing 50µg/ml Ampicillin, and 
incubated in a 37o C shaker at 220-rpm overnight. Inoculation of bacterial cells into LB 
growth medium was performed close to an open flame fire to prevent air borne bacteria 
from contaminating the media. These overnight cultures were used for Qiagen Mini Prep, 
or as a starter culture for Qiagen Maxi Prep and transferred into 250 ml LB medium for 
another overnight incubation at the same conditions. 
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3.1.8 Work with Mammalian Cell Lines 
 
Handling of Human Cell Lines 
 
Handling and propagation of all cell lines were performed in a cell and tissue culture 
laminar-flow hood under sterile conditions. All solutions were stored at 4o C and warmed 
up to 37o C in a water-bath before using. All solutions were only opened under sterile 
conditions in a hood. Cell culture media and FCS used for all cell lines were sterile 
filtered in the hood. All cell lines were grown in IMEM 10 % FCS, except the cell 
line1205 LU was grown in ¾ Keratinocyte-SF-Medium, ¼ Leibovitz’s L15 Medium, 5 % 
FBS.  
 
Thawing of Cultured Human Cell Lines 
 
The cell line aliquots were stored in 1 ml freezing medium at –80o C. To grow up a cell 
line the freeze down was thawed quickly in a 37o C water-bath then transferred into a 
15ml tube and mixed with 10 ml of medium. The suspended cells were centrifuged at 
1,000 g for 5 min. in order to isolate a cell pellet free of DMSO residues from the 
freezing medium. After removing the supernatant the pellet was resuspended in 10 ml 
medium and transferred into a T75 cm2 cell culture flask. The cells were stored in a 5 % 
CO2, 37o C incubator. 
 
Maintenance of Human Cell Lines 
 
All cell lines were grown in a 37o C incubator and split in certain ratios depending on the 
stage of confluence and the proliferation rate of each cell line. The amount of medium 
added to the flask was dependent on its size. 10 ml were added into T75 flasks whereas 
20 ml were added to the T 164 flasks. The medium was changed every other day.1/10 of 
the amount of culture medium was used as the amount of Trypsin/EDTA supplied to a 
culture flask in order to detach the cells. To split cells the medium was completely  
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aspirated from the flask and the cells were washed briefly with 2 ml of Trypsin to remove 
traces of Antitrypsin originating from the serum in the media. After removing the Trypsin 
another 2ml Trypsin were placed into the T 164 and 1 ml into the T 75 flasks. The cells 
detached after about 5 min with occasional gentle tapping. The Trypsin was then 
immediately inactivated by adding 3ml of medium to each flask. This suspension was 
transferred into a 50ml tube and centrifuged at 1,000 g for 5 min. The supernatant was 
aspirated and the cell pellet was resuspended in medium and split into 3 to 5 new flasks. 
For each experiment, each individual cell line was pooled during the splitting process to 
assure equal amounts of cells plated into each flask. 
 
Freezing Cultured Human Cell Lines 
 
To freeze cells for long term storage, cells were harvested (at least one T75 flask of 80 % 
confluent cells) and centrifuged at 1,000 g for 5 minutes. The media was then aspirated 
and cells were resuspended in 1 ml of cell culture freezing medium. The resuspended cell 
solution was transferred to Cryo-tubes and placed at –70o C in an isopropanol-containing 
cell freezing container, which guarantees a slow freezing process. After 24 hours the tube 
can be stored at –70oC in a regular box. 
 
 
3.2 The BP2 cDNA BAC clone 
  
The FGF-BP2 full length sequence was obtained from a human chromosome 4 BAC 
clone C0024K08 (GenBank accession number AC005598), where it is covering the 
sequence between nucleotides 132697 – 135582. The BP2 open reading frame cDNA 
extending from an ATG start codon at nucleotide 64 to a TGA stop codon at nucleotide 
736 was already cloned into the BamHI/XbaI site of the pC4 vector which was kindly 
provided by Dr. Yanggu Shi, Human Genome Sciences, Rockville, MD, USA. The pC4 
vector is a Human Genome Sciences in-house vector. This construct consists of a CMVmi 
promotor driving expression of the full length ORF of FGF-BP2. 
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3.3 Cloning of the FGF-BP 2 cDNA into the Vector pCR ® 3.1 
  
For further work with the FGF-BP2 cDNA, the BamHI/XbaI fragment from the vector 
pC4, containing the FGF-BP2 cDNA, was subcloned into pCR ® 3.1 which is a 
commercially available vector. The pCR® 3.1 vector contains BamHI and XbaI sites in 
its multiple cloning site. It was ensured that neither of the restriction endonucleases 
would cut inside of the insert by checking the nucleotide sequence for the enzymes’ 
restriction sites. The new construct was named pCR3.1/ FGF-BP2. 
 
3.3.1 Restriction Digest of the Expression Vector pC4 
 
For subcloning purposes 20 µg of the plasmid DNA of the pC4 vector was digested with 
two restriction endonucleases to obtain the FGF-BP2 ORF insert. The restriction reaction 
was carried out in a total volume of 50 µl, containing the plasmid DNA, 30 U of the 
restriction endonuclease BamHI, 30 U of the restriction endonuclease XbaI and 10% of 
NEBuffer 2. To start the reaction, the restriction endonucleases were added last and the 
reaction was incubated at 37o C for 1 hour to allow the enzymes to work at optimal 
condition. After that 1µl of the sample was loaded on a DNA gel for electrophoresis. 
Samples were run on the gel with a 1 kb DNA marker at 40 Volts for 120 min. The gel 
was checked on an UV light box for a correct, complete digest and the presence of a 
700bp insert. The total amount of the restriction reaction was loaded on a DNA gel and 
separated. 
 
3.3.2 Gel Extraction 
 
The FGF-BP2 cDNA insert was obtained by gel extraction according to the Qiagen Gel 
Extraction Kit protocol. The insert was then cut out of the gel using a sterile razorblade 
and placed into a microfuge tube. The total weight of the gel containing the BP2 fragment 
was about 200 mg. The first step was to solubilize the gel slice by adding 3 volumes (µl) 
of Buffer QX1 to 1 volume (mg) of gel. Next DNA was bound to the silica particles in  
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the QIAEX II suspension by adding 30µl of QIAEX II to the sample and incubating at 
50o C for 10 min. The sample was vortexed every other minute to keep the silica particles 
in suspension. The buffer QX1 contains a pH indicator, which allowed the optimal pH at 
< 7.5 for DNA adsorption to be determined. Next, the sample was centrifuged for 30 sec 
and the supernatant was removed. To remove residual agarose 500 µl of Buffer QX1 
were added, the pellet was resuspended by vortexing, centrifuged for 30 sec and the 
supernatant was removed. To remove residual salt contaminants the pellet was washed 
twice in 500 µl of Buffer PE. After vortexing the sample to resuspend the pellet and 
subsequent centrifugation all traces of supernatant were removed. The pellet was air-
dried for 10 min. Afterwards the DNA was eluded by resuspending the pellet in 20 µl 
H2O. The sample was incubated for 5 min at room temperature. The resuspention was 
then centrifuged and the supernatant, now containing the purified DNA, was removed. 
The DNA concentration was determined by spectrophotometry. 
 
3.3.3 Linearization of the Vector pCR® 3.1 
 
The BP2 cDNA digested with BamHI and XbaI was ligated into the BamHI site of the 
expression vector pCR® 3.1. To accomplish this, the vector first had to be cut at its 
BamHI and XbaI sites to linearize it, allowing ligation of the insert at this site. The 
linerization of the vector was performed in a total volume of 50 µl. 20µg of the vector 
were digested in 10 % NEBuffer2 with 30 U BamHI and 30 U XbaI under the same 
conditions as described in 3.3.1. Next, the linearized vector was purified by gel extraction 
in the same procedure as described in 3.3.2. The concentration was determined.  
 
3.3.4 Ligation of theFGF-BP2 ORF into the Vector pCR® 3.1 
  
The FGF-BP2 insert was ligated into the BamHI/XbaI site of the pCR® 3.1 vector. The 
ligation reaction was carried out in a total volume of 10µl. The ligation was set up in a  
1 : 23 molar ratio of vector : insert. 50 ng of the linearized vector were resuspended in 
2µl H2O, 150 ng of the insert were resuspended in 1µl H2O. 5 µl of H2O, 1 µl of 10x  
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Ligation Buffer and 1µl of T4 DNA Ligase were mixed with the vector and the insert and 
the ligation were incubated at 16 o C for 6 hours. 
 
 
3.4 Transformation of the DH5α™ Cells with the FGF-BP2 Plasmid 
  
In order to obtain plasmid DNA for purposes of transfection, sequencing and generating 
probes, the vector containing the cloned FGF-BP2 ORF was transformed into a clone of 
DH5α ™ bacterial cells. The competent cells were removed from a -70o C freezer and 
thawed on ice. Next, 2 µl of mercaptoethanol and 5ng of DNA, in 2 µl of the ligation 
reaction, were added to a 100 µl aliquot of the cells. The tube was gently tapped to mix 
and then incubated on ice for 30 min. To heat shock the cells after the incubation, the 
sample was placed in a 42o C water bath for 45 sec, and then placed on ice for two 
minutes. 450 µl of LB medium was added, and the sample was amplified by incubating 
for 1 hour at 37o C while shaking at 225 rpm. A 1:10 dilution of the sample was made 
and 100 µl of the dilution was spread out on LB agar growth plates containing 100µg/ml 
Ampicillin. The plate was incubated in a bacterial cell incubator at 37o C overnight. 
Transformed bacteria form a single colony growth on the Ampicillin selective milieu. 
The growth plates were stored at 4o C  
 
 
3.5 DNA Plasmid Purification 
  
DNA plasmids were purified for purposes of analytical restriction digests, sequencing 
and generation of probes. The plasmid purification was achieved by using Qiagen 
QIAprep Miniprep Kit for plasmid screening of transformed bacterial colonies and 
Qiagen Plasmid Maxiprep Kit for purification of larger amounts of DNA for sequencing 
and generation of probes. 
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3.5.1 Qiagen Miniprep DNA Plasmid Isolation 
  
Bacterial cells were inoculated and incubated (3.2.1) in 5 ml LB medium containing 
50µg/ml Ampicillin. The cultured cells were centrifuged at 3,000 x g for 10 min in order 
to form a bacterial cell pellet. The medium was aspirated and the pellet was resuspended 
in 250µl Buffer P1, containing RNase A, and transferred into a fresh tube. For alkaline 
cell lysis 250µl Buffer P2 (NaOH/SDS) were added and mixed with the solution by 
gently inverting the tube. The lysis reaction, that solubilizes the phospholipids and 
proteins of the cell membrane (SDS) and denatures the chromosomal and plasmid DNA 
(NaOH), was allowed to proceed for 5 min. Then 350µl of Buffer N3 were added for 
neutralization purposes. To avoid any localized precipitation, the solution was mixed 
immediately after the addition of buffer. The sample was centrifuged at 3,000 x g for 15 
min. The cell debris and SDS precipitant form a pellet. The plasmid DNA is in 
suspension in the supernatant, which was then transferred to a QIAprep spin column and 
centrifuged at 3000g for 1 min. The silica-gel membrane ensures a selective absorption of 
plasmid DNA in high salt buffer. To wash the column salt contaminants, 750µl Buffer PE 
were added and centrifuged for 1 min at 3000g. To elute plasmid DNA, the column was 
placed on a clean microfuge tube and 30µl H2O were added in the center of the column 
and collected. After waiting for 3 min the column was centrifuged at 3000g for 1min. 
Due to the low salt concentration of the H2O the plasmid DNA is eluted from the column. 
The DNA yield was defined by spectrophotometric reading. 
 
3.5.2 Qiagen Maxiprep DNA Isolation 
 
The plasmid DNA purification principle according to the Qiagen Maxiprep is similar to 
the process of the Qiagen Miniprep. Bacterial cells were incubated in 250 ml LB 
medium, containing 100µg/ml Ampicillin. To harvest the bacterial cells, the culture was 
centrifuged at 6,000 x g for 15 minutes. All traces of supernatant were removed and the 
bacterial cell pellet was resuspended in 4ml Buffer P1 (RNase added). The suspension 
was transferred into a fresh tube and 4 ml of Buffer P2 were added. The solution was  
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mixed and incubated at room temperature for 5 min. Next, 4 ml of chilled Buffer P3 were 
added and immediately mixed with the solution. The sample was incubated on ice for 15 
min and then centrifuged at 20,000 x g for 30 min at 4o C. Meanwhile Qiagen-tip 100 
columns were equilibrated by applying 4 ml Buffer QBT on the column and allowing it 
to empty by gravity flow. The supernatant from the centrifugation was immediately 
removed and applied to the equilibrated column and allowed to enter a resign by gravity 
flow. Afterwards the column was washed twice with 10 ml of Buffer QC. Adding 15 ml 
of Buffer QF onto the column eluted the plasmid DNA. The DNA then was precipitated 
by adding 10 ml isopropanol. The sample was mixed and subsequently centrifuged at 
15,000 x g for 30 min at 4o C. The supernatant was decanted and the DNA pellet was 
washed with room-temperature 70% ethanol and centrifuged at 15 000g for 10 min. The 
supernatant was aspirated and the pellet was air- dried for 5-10 min. The plasmid DNA 
then was dissolved in 50-100 µl H2O and the concentration was determined.  
 
 
3.6 Sequencing of theFGF- BP2 ORF 
 
To verify the correct subcloning of the FGF-BP2 insert the plasmid DNA was sequenced. 
The sequencing was provided by the Lombardi Cancer Center Sequencing Core Facility. 
The sequencing was done by automated cycle sequencing (ABI PRISM Dye Terminator 
Cycle Sequencing, Perkin-Elmer). The pCR® 3.1 vector contains a T7 promotor/priming 
site at the 5’end of the multiple cloning site which was used as the sequencing primer. An 
amount of  500 ng of the purified plasmid DNA was used for the sequencing. 
 
 
3.7 Stable Transfection of the Cell Line SW13 
 
The expression vector pCR® 3.1 containing the FGF-BP2 cDNA was stably transfected 
into the SW-13 cell line. This cell line originates from an adrenal cell carcinoma and is 
non-tumorgenic. The SW 13 cells were transfected with the pCR ® 3.1 vector containing  
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the FGF-BP2 ORF whose expression is driven by the CMV promoter. The cells were also 
transfected with an empty pCR3.1 vector as a negative control. The stably transfected 
cells were selected after Geneticin® (G418) treatment. The SW 13 cells were grown to 
50-70 % confluency (2 x 105) in T75 cm2 flasks. Then 1µg of the plasmid DNA was 
diluted in 100µl OPTI–MEM® I reduced serum medium. In a second tube 7µl of 
LIPOFECTAMINE was diluted in 100µl of OPTI–MEM® I. Both solutions were combined, 
gently mixed and incubated at room temperature for 30 min to allow DNA-liposome 
complexes to form. Meanwhile the cells were rinsed in serum-free medium. 0.8 ml OPTI-
MEM® I was added to the tube containing the complex. The sample was mixed gently 
and the diluted complex solution was overlaid onto the rinsed cells. The cells were 
incubated with the complexes for 5 hours at 37o C in a 5% CO2 incubator. The 
transfection medium was then replaced with IMEM 10 % FCS and incubated for 24 
hours. The stably transfected cells were selected by culturing them in IMEM 10% FCS in 
the presence of 500µg/ml Geneticin® with a medium change every other day. The 
expression of the BP 2 ORF was shown by Northern Blot Analyses. 
 
 
3.8 Soft agar growth assay 
 
In order to examine a potential role of FGF-BP2 in tumor growth the SW-13 cell line was 
used as model system. This cell line expresses high levels of FGF-2, but lacks both FGF-
BP1 and FGF-BP2 expression. (Introduction 2.5 Results 4.6). Furthermore, wild type 
SW-13 cells do not form colony in soft agar unless they are supplemented with 
exogenous FGFs or transfected with FGF genes with secreted signal peptides (Wellstein 
et al. 1990). To study an anchorage-independent growth of the FGF-BP2 transfected SW-
13 cells a soft agar assay was carried out. The SW-13 cells, transfected with the empty 
vector were used as a control. Melted, pre-sterilized Bactoagar in a concentration of 1.2g 
inn 50ml water was mixed with 100ml of IMEM, 50ml of 2x IMEM, and 20% of FCS 
and kept at 42-44 C. From this stock, a 1-ml bottom layer of 0.6% agar was formed in 35-
mm dishes and allowed to solidify at room temperature. The transfected SW-13 cells  
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were cultured, grown and harvested as previously described and suspended in a 
concentration of about 10,000 – 20,000 cells in 0.5 ml total volume. This cell suspension 
mixed with an equal volume of culture medium, in some experiments containing FGF-1 
or FGF-2 in various concentrations (0.05, 0.10, 0.25, 0.50, 1.00 ng/ml) and 1.5g of the 
agar stock solution. This suspension (0.36% of agar) was layered onto the bottom layer 
(0.8 ml/dish), and allowed to solidify. The dishes were then incubated at 37 C for 10 – 14 
days. The number of colonies of 40 – 60 µm in diameter were hereafter counted using an 
image analyzer. All experiments were carried out in triplicate sets of dishes. 
 
 
3.9 Preparation of cDNA Probes for Northern Blot Analysis 
 
The aim of the Northern Blot Analysis is to pick up a mRNA signal out of the total RNA 
of a cell line or tissue homogenate. To accomplish this the single stranded denatured 
RNA is exposed to a radioactive labeled and denatured DNA probe in order to form a 
hybridization between the two complementary nuclic acids strings. The two cDNA 
molecules used were the FGF-BP2 ORF cDNA , the FGF-BP1 cDNA and the cDNA 
coding for glyceraldehyde-3 phosphate dehydrogenase (GAPDG). GAPDH is an essential 
enzyme and ubiquitously expressed in every used cell line. Therefore, the GAPDH 
mRNA expression was used as a loading control and the FGF-BP2 mRNA expression 
level was normalized to it. 
The GAPDH cDNA from Clontech is commercially available. The FGF-BP2 cDNA open 
reading frame is 700bp long, and was obtained by digesting it out of the multiple cloning 
site of the pCR ® 3.1 vector, where it was previously cloned. (Methods 3.3) 
 
3.9.1 DNA Isolation  
 
A single colony of FGF-BP2 transformed E.coli DH5α was picked from an Ampicillin 
selective LB bacterial growth plate inoculated and incubated (Methods 3.1) in order to  
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perform a DNA Isolation according to Qiagen Plasmid Maxi Kit (Methods 3.5). The total 
plasmid DNA was diluted in 100 µl H2O. 
 
3.9.2 Digestion of the FGF-BP2 Fragment  
 
For generation of the hybridization probe plasmid DNA was digested with the restriction 
endonucleases BamH I and Xba I which cut at either end of the FGF-BP2 ORF in the 
multiple cloning side, producing the 700 bp FGF-BP2-ORF insert as a fragment. The 
restriction was performed in a total volume of 50 µl, containing 50 µg of the plasmid 
DNA, 10 % NEBuffer2, 30 U of the restriction endonuclease BamH I and 30 U of the 
restriction endonuclease Xba I. The restriction reaction was carried out in the same 
conditions as described in 3.2.3. To test for complete digestion a sample of 1µl of the 
reaction was loaded on a DNA gel for electrophoresis. After electrophoresis the DNA 
fragments were visualized on an UV light box to judge the correct and complete digest. 
The now linearized plasmid runs at 5 kb where as the FGF-BP 2 open reading frame runs 
at its size of 700 bp, identified by comparison with the 1kb DNA molecular weight 
marker. The total digest was loaded on the gel, separated and the insert was cut out from 
the gel by using a sterile razorblade. Any excess agarose was carefully removed. The 
isolated gel section, containing the FGF-BP 2 insert, was placed in a tube. 
 
3.9.3 Gel Extraction 
 
The gel extraction was accomplished by using the Qiagen QIAEX II Gel Extraction Kit. 
The estimated amount of the restricted FGF-BP 2 cDNA insert, 1/8 of the total volume, 
was about 6 µg. The total amount of gel containing the cDNA was about 200 mg. The gel 
extraction was accomplished as described in 3.2.3. As a result the FGF-BP2 ORF cDNA 
was obtained. 
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3.9.4 Radioactive Labeling of the Probe for Northern Blot Analysis 
 
For hybridization purposes the FGF-BP2 cDNA fragment was radioactive labeled. The 
incorporation of radioactivity in the cDNA was achieved by random prime labelling 
according to the Amersham rediprime™ II random prime labelling system protocol. At 
first 50-100 ng of cDNA were diluted in 45 µl H2O. The dilution was denatured by 
incubating it at 90o C for 10 min and a subsequent cold shock on ice. The denatured DNA 
was added to the labeling reaction mix, which consists of a buffered solution of dATP, 
dGTP, dTTP, Klenow enzyme and random primers in a dried stabilized form. The tube 
was flicked until a complete suspension was achieved. Then 5 µl of α-(32P) dCTP were 
added and mixed with the solution. The sample was incubated at 37o C for 30 min in 
order to allow the nucleotides to form a complementary strand to the single stranded 
DNA. The primers bind randomly to the DNA strand and allow the Klenow enzyme, an 
exonuclease free particle of the DNA polymerase I, to polymerize the nucleotides 
complementary to the ssDNA fragment, incorporating the radioactive dCTP. The next 
step is to purify the DNA fragments from the free nucleotides. For this gel-filtration 
chromatography is used. A micro-spin S-200® spin column was centrifuged for 1 min at 
3000g to eliminate the equilibration buffer. Then the sample was loaded onto the spin 
column and centrifuged for 3 min at 3,000 x g. The larger DNA fragments are eluded into 
a tube beneath the column, whereas the free nucleotides get stuck in the gel particles of 
the chromatography column. The eluted DNA strands were denatured to ssDNA by 
heating to 90o C and immediate shocking on ice. The amount of incorporated 
radioactivity was determined before using the ssDNA as a hybridization probe. For 
quantification 2µl of the sample were diluted in 2ml-scintillation fluid and the activity in 
cpm was determined in a scintillation counter. 
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3.10 RNA Isolation from Mammalian Cell Lines 
   
3.10.1 Homogenization  
 
In order to isolate the total RNA for a subsequent Northern Blot Analysis, the cells were 
grown in T75 cm2 flasks in a monolayer to 80 % confluency. After aspirating the 
medium, the cells were directly lysed in the flask by adding 1 ml RNA STAT-60™. This 
latter is a phenol/guanidinium isothiocyanet (GTC) solution, which acts to homogenize 
the cells by denaturing proteins and disrupting membrane structures. The solution was 
distributed equally in the flask and an immediate cell lyse was visible. The total harvest 
was collected by scrapping, then homogenized by repetitive pipetting and transferred into 
a tube. The homogenate was stored at room temperature for 5 min. to permit the complete 
dissociation of nucleoprotein complexes.  
 
3.10.2 Extraction 
 
For the extraction of the RNA 0.2 ml of chloroform per 1ml of RNA Stat-60™ were 
added, the sample was vortexed for 15 sec and left at room temperature for 3 min. Next, 
it was centrifuged at 12,000 x g for 15 min at 4 C. Following the centrifugation, the 
homogenate separates into three phases, a lower organic phenol/chloroform phase, an 
interphase and an upper aqueous phase. This step serves to extract proteins by confining 
them to the organic phase, separating the DNA into the interphase while leaving the 
ribonucleic acid remaining exclusively in the aqueous phase. 
 
3.10.3 Precipitation 
 
For precipitation of the RNA, the aqueous phase was transferred to a fresh tube and 
mixed with 0.5 ml isopropanol per 1 ml RNA Stat-60™ used for homogenization by 
vortexing the sample for 15 sec. The sample was kept at room temperature for 10 min.  
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and then centrifuged at 1,200 x g for 10 min. at 4 C. Afterwards the RNA precipitate 
forms a visible pellet at the bottom of the tube. 
 
3.10.4 Washing 
 
The supernatant was removed and the pellet was washed in 75 % ethanol by vortexing 
and subsequent centrifugation at 10,000 x g at 4o C. 1 ml ethanol was used per1 ml RNA 
Stat-60™ used initially. The supernatant was aspirated from the pellet and the RNA was 
briefly air-dried. Each sample was dissolved in 50 µl DEPC-H2O. 
 
 
3.11 Northern Blotting Analysis 
 
By Northern Blot Analysis, the expression stage of a gene from a certain cell line can be 
identified. A Northern Blot Analysis can not only define the presence of a particular 
mRNA, but also quantify its amount of expression in a certain cell line or tissue 
homogenate. 
 
3.11.1 Preparation and Electrophoresis of RNA Samples 
 
RNA samples for Northern Blot Analysis were prepared so that each sample contained 
20µg of total RNA harvested from a single cell culture flask, diluted in a volume of 20 µl 
loading buffer. For this purpose the speedvac concentrator was used to reduce the volume 
of each RNA sample to a volume of approximately 2 µl, using caution not to dry the 
sample completely, as it will greatly decrease its solubility. Then 20 µl of RNA loading 
buffer were added to each sample, mixed and incubated at 65 C for 15 min. to linearize 
the RNA. The samples were loaded on an RNA gel and separated by electrophoresis. 
Afterwards the gel was inspected under UV light to ensure the RNA was separated. The 
very visible rRNA bands (18s at1874bp and 28s at 4718bp) were used as a good  
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indication of the fractionation status of the RNA. Any possible degradation of the RNA 
was checked for under UV light, detectable as a smear in the lane. A photograph of the 
gel next to a ruler was taken. 
 
3.11.2 RNA Transfer to Nylon Membrane 
 
For hybridization purposes, the RNA has to be transferred from the Formaldehyde gel to 
a nylon membrane. This transfer was performed via capillary action from the agarose gel 
to a solid support using 10 x SSC as a transfer buffer. The buffer is drawn from a 
reservoir and passes through the gel into a stack of paper towels. The RNA is eluded 
from the gel by the moving stream of buffer and deposited on a nylon membrane, which 
was placed between the gel and the paper towels. A weight applied to the top of the paper 
towels ensured a tight connection between all layers of material used in the transfer 
system, which is important for a sufficient and equal transfer. Two pieces of Whatman 
paper were cut to equal width but greater length of the gel. They were placed on a plate 
above a bowl with its longer ends hanging into the bowl filled with 1 L 10x SSC transfer 
buffer. The gel was placed upside down on top of the Whatman paper. To remove 
bubbles a sterile pipette was rolled over the gel. Parafilm stripes were used to surround 
the gel ensuring the buffer would pass only through the gel to the paper towels. The 
Nylon Membrane was cut to the size of the gel, soaked in the transfer buffer and placed 
on top of the gel. Any occurring air bubbles were also removed. Additional two layers of 
Whatman paper, cut to the size of the gel, were arranged on top of the membrane, 
followed by a stack of gel sized paper towels and a weight. Gel and membrane were 
exposed to this transfer system overnight. To verify a complete and even transfer of the 
total RNA, gel and membrane were checked under UV light to determine if any RNA 
remained in the gel and to mark the 18s and 28 s bands on the membrane. 
 
 
 
 
Methods  47 
 
3.11.3 RNA Fixation to the Nylon Membrane 
 
After the transfer was carried out the RNA was immobilized on the Nylon Membrane. 
The RNA was fixed to the membrane by crosslinking it via an exposure to low doses of 
ultraviolet irradiation. This was accomplished by the use of an UV crosslink apparatus at 
an energy level of 120 000 microjoules/cm2, utilizing a 254-nm light source. This 
procedure forms a covalent bond between the positively charged amino groups of the 
nylon and the uracil bases of the RNA. Caution was used not to overirradiate, which 
otherwise would result in the covalent attachment of a higher proportion of uracil, with a 
consequent decrease in hybridization signal. 
 
3.11.4 Prehybridization  
 
The crosslinked Nylon membrane was placed rolled inside a hybridization tube with the 
RNA side facing inward to get a maximum contact with the solution. Before it is possible 
to hybridize the membrane it is essential to complete a prehybridization to prevent 
nonspecific binding signals. The 5 x Denhardt’s buffer and 10 µg/ml denatured Salmon 
Sperm DNA were supplemented to a total of 10 ml prehybridization solution. To 
denature the Salmon Sperm DNA it was placed in a 90o C heat block for 10 min and 
chilled quickly on ice before it was pipetted into the prehybridization solution. The 
solution was transferred into the hybridization tube and incubated for 2-5 hours at 42 C in 
a Hybridization oven under permanent agitation. 
 
3.11.5 Hybridization 
 
After sufficient prehybridization to minimize unspecific binding the membrane was 
hybridized with the specific probe. The radioactive labeled strand cDNA used to detect 
the desired specific signal was denatured in order to allow hybridization with its 
complementary RNA on the membrane. Denaturing of the labeled cDNA was achieved 
by heating it in a 90o C heat block for 10 min and subsequent cold shock on ice before  
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adding the probe into the existing prehybridization solution. The final concentration of 
the labeled probe was always greater than 106 cpm/ml hybridization solution. The 
hybridization was carried out overnight at 42o C under constant agitation in the 
hybridization oven. 
 
3.11.6 Washing 
 
Different washing steps were carried out to carefully remove background radioactivity, 
by eliminating unspecific binding. The stringency of the washing steps were varied, with 
increases in higher temperature and decreases in lower salt concentration. For each 
specific signal the right conditions were determined according to the strength of the 
signal, using caution to wash enough background but not the specific signal. The three 
performed washing rounds were ordered in an increasing stringency. Subsequent to 
removing the hybridization solution, the blot was first rinsed in 100ml of 2x SSC for 5 
min at room temperature. The next step was washing in 100ml 2x SSC, 1.0% SDS at  
50o C under constant agitation in the hybridization oven for 30 min. Finally, the blot was 
washed in 100 ml 0.1 x SSC at room temperature for 30 min. The hybridized membrane 
was removed from the bottle and immediately sealed in a plastic bag. 
 
3.11.7 Autoradiography of Hybridized Membranes 
 
The sealed radiolabelled membranes were placed between two intensifying screens and 
exposed to an X-ray film to obtain an autoradiographic image. The exposure time was 
varied between 6-24 hours according to the intensity of the signal. For maximum 
intensity the film cassette was placed at – 70 C. The quantitation of mRNA levels for the 
cell lines 1205 LU, SK-MEL 5 and the FGF-BP2 transfected SW 13 were done by using 
a Phosphor imager screen. The blot was exposed to the screen for 24-48 hours at room 
temperature, scanned and then analyzed by the quantitation software program 
ImageQuant. 
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3.12 Cell Line Treatment with EGF, TPA, Fetal Bovine Serum  
and all-trans-retinoic Acid 
 
For the purpose of the FGF-BP2 mRNA regulation study, the 1205LU, SK-MEL 5 and 
the FGF-BP2 transfected SW 13 cell lines were treated in culture with growth factors and 
drugs in certain concentrations and at different time points. The cell lines were treated 
with bFGF, EGF, TPA and all-trans-retinoic Acid. The mRNA expression level 
corresponding to the effect of the treatment was visualized by Northern Blot Analysis. 
The cells were equally distributed in a determined number of T75 flasks and grown to 
80% confluency in their regular FCS containing medium. All residues of serum were 
washed off before adding the drug. This was achieved by washing the cells twice in 
serum free medium, then incubating them in serum free medium overnight and an 
additional serum free medium change before adding serum again or a drug or a growth 
factor. In this study fetal bovine serum (FBS) was used in concentrations of 5 % and 10 
%. All-trans-retinoic acid (tRA) was used in concentrations of 10 –5 M, 10 –6 M, 10-7 M, 
10-8 M and 10-9 M. The growth factors Basic Fibroblast Growth factor (bFGF) and Basic 
Epidermal Growth Factor (EGF) as well as the Phorbol ester TPA were also used to treat 
the cell lines, although the obtained data is not shown in the results. The different agents 
were all added directly into the 10 ml medium of the T75 flasks in a final volume of 10µl. 
It was ensured that the drug or growth factor was equally distributed in the flask by 
carefully shaking it. Since all-trans-retinoic acid and the phorbol ester TPA are diluted in 
100% DMSO this vehicle achieves a final concentration of 0.1% in the medium. 
Therefore it was obligatory to add the same concentration of DMSO to a control flask in 
each experiment, which was not treated with either tRA or TPA. This was necessary to 
determine the effect to the drug and exclude the possibility that the effect was due to the 
vehicle. The flasks were stored in the incubator until the time point of harvesting. In this 
study different time points of harvesting the cells were taken. Cells were harvested after 
30 min, 1 hour, 2 hours, 3 hours, 5 hours, 6 hours 12 hours 20 hours and 24 hours. 
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4.1 Genomic Sequence Analysis of FGF-BPs 
 
The FGF-BP1 gene is located on one of the six unordered genomic DNA pieces derived 
from the BAC clone C0024K08 for human chromosome 4 (Accession number 
AC005598). On the basis of the human FGF-BP1 cDNA sequence, which was published 
by Wu et al (Wu et al., 1991), an amino acid sequence search revealed that about 22kb 5’ 
upstream of the FGF-BP1 transcription start site lies a gene with the closest homology 
(Figure 4). We named this gene FGF-BP2. This gene is structured into 2 exons, that are 
separated by an 1.8 kb intron. The entire ORF is located on exon 1. Both genes are in the 
same transcription orientation. The deduced amino acid sequence of FGF-BP2 revealed 
that the translated protein is composed of 233 amino acid residues with a Mr of 24.5 kDa, 
including a putative 19 amino acid signal peptide. Using GeneMap of human genome, 
both human FGF-BP1 and FGF-BP2 genes are found to reside on the short arm of human 
chromosome 4 between D4S412 and D4S1601 (3.7 – 28.2 cM) microsatellite anchor 
markers. 
 
Figure 4: Gene Structures of FGF-BP1 and FGF-BP2 
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Intron Intron
FGF-BP1FGF-BP2
 
 
Figure 4: Gene Structures of FGF-BP1 and FGF-BP2. The genes for FGF-BP1 and FGF-BP2 
were located on a BAC clone for human chromosome 4. The open reading frame (ORF) of FGF-
BP1 and its 3’ untranslated region are located on exon 2. Exon 1 contains the 5’ untranslated 
region separated from exon 2 by an intron of 1.6 kb. About 22kb 5’ upsteam of the FGF-BP1 
transcription start site is exon 2 of FGF-BP2 containing the 3’ untranslated region. The entire 
ORF of FGF-BP2 is located on exon 1 separated from exon 2 by an intron of 1.8kb. 
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4.2 Cloning of the FGF-BP2 ORF into the Vector pCR® 3.1 
 
The FGF-BP2 open reading frame was received as a gift from Dr. Yanggu Shi of Human 
Genome Sciences. The gene was cloned into the BamHI/XbaI restriction site of the pC4 
expression vector, which is a Human Genome Sciences in house vector. For further work 
with the gene the FGF-BP2 ORF it was now subcloned into the commercially available 
expression vector pCR® 3.1 (Figure 5). The FGF-BP2 ORF was released from the pC4 
vector by restriction digest reaction using the restriction endonucleases BamHI and XbaI 
(Methods 3.3.1). The insert was purified (Methods 3.3.2), the vector pCR® 3.1 was 
lineraized (Methods 3.3.3) and the insert was ligated into the BamHI/XbaI sites of the 
multiple cloning site of the vector pCR® 3.1 (Methods 3.3.4). 
 
Figure 5: Cloning of the FGF-BP2 cDNA 
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Figure 5: Cloning of the FGF-BP2 cDNA. The FGF-BP2 open reading frame was cut out of the 
BAC clone for human chromosome four and cloned into the BamHI/XbaI site of vector pC4. For 
further studies the ORF was then cloned into the BamHI/XbaI site of the pCR ® 3.1 expression 
vector. 
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4.3 Transformation of the DH5α ™ Cells with the FGF-BP2 Plasmid and 
Purification of the Plasmid 
 
The subcloned FGF-BP2 plasmid was transformed into DH5α ™ Cells to amplify the 
plasmid DNA (Methods 3.4). Selected bacterial colonies were picked and grown, and the 
plasmid DNA was purified (Methods 3.5). Analytical restriction digest reactions were 
performed to show a correct insertion of the insert. 
 
 
4.4 Sequence Analysis of the subcloned FGF-BP2 and Comparison  
to FGF-BP1 
 
The newly subcloned FGF-BP2 ORF was sequenced for its nucleotide structure (Methods 
3.6), both to verify the correct subcloning and to compare to the FGF-BP1 gene. The 
isolated full length FGF-BP2 cDNA contains 1120 base pairs excluding the poly-(A) tail, 
and its sequence is mapped between nucleotides at position 132636 and 135582 on the 
BAC clone described above. The ORF extends from an ATG start codon at nucleotide 64 
to a TGA stop codon at nucleotide 736. There is no homology between FGF-BP1 and 
FGF-BP2 nucleotide sequences. The deduced amino acid sequence of FGF-BP2 contains 
223 amino acids with a Mr  of 24.5 kDA and a pI of 9.15. Using a computer program 
predicting prokaryotic and eucaryotic signal peptides and their cleavage sites (Nielsen et 
al., 1997), the signal peptide for FGF-BP2 would consist of the first 19 amino acid 
residues with the potential cleavage site occurring between G19 – Q20. Deduced amino 
acid sequences of FGF-BP1 and FGF-BP2 are aligned for comparison (Figure 6). This 
comparison shows that FGF-BP2 has a 21% amino acid identity and a 41% homology 
with respect to FGF-BP1. Both FGF-BPs contain 8 conserved cysteine residues. This 
might suggest that these disulfide bridges involved in the formation of a tertiary structure 
are critical of the function of the proteins. 
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Figure 6: Deduced Amino Acid Sequence of FGF-BP2 
 
FGF-BP 2:    24    QKQGSTGEEFHFQTGGRDSCTMRPSSLGQGAGEVWLRVDCRNTDQTYWCEYRGQPSMCQA     83 
                     +++   G +  F T  + +C    +   +G   + L+V+C   D  + C + G P+ C   
FGF-BP 1:    49    KQKSRPGNKGKFVTKDQANCRWAATEQEEG---ISLKVECTQLDHEFSCVFAGNPTSCLK    105 
 
 
FGF-BP 2:    84    FAADPKPYWNQALQELRRLHHACQ-GAPVLRPSVCREAGPQAHMQQVTSSLKGSPEPNQQ    142 
                        D + YW Q  + LR     C+     ++  VCR+  P++ ++ V+S+L G+ +P ++ 
FGF-BP 1:   106    L-KDERVYWKQVARNLRSQKDICRYSKTAVKTRVCRKDFPESSLKLVSSTLFGNTKPRKE    164 
 
 
FGF-BP 2:   143    PEAGTPSLRPKATVKLTEATQLGKDSMEELGXXXXXXXXXXXXXXXGPRPGGNEEAKKKA    202 
                            + P+  +K       GK++                     P        +K A 
FGF-BP 1:   165    ----KTEMSPREHIK-------GKETTPSSLAVTQTMATKAPECVEDPDMANQ---RKTA    210 
 
 
FGF-BP 2:   203    WEHCWKPFQALCAFLIS    219 
                      E C + + +LC F +S 
FGF-BP 1:   211    LEFCGETWSSLCTFFLS    227 
 
 
 
Identities = 42/197 (21%), Positives = 82/197 (41%), Gaps = 19/197 (9%) 
 
 
Figure 6: Deduced Amino Acid Sequence of FGF-BP2. The deduced amino acid sequence of 
FGF-BP2 is aligned with that of FGF-BP1 for comparison. Identical amino acids are matched by 
their short form in the middle, amino acids with homology to each other are matched by (+) and 
conserved cysteine residues are in bold letters. 
 
 
4.5 Generating a Hybridization Probe for Northern Blot Analysis 
  
The FGF-BP2 ORF insert was cut out of the purified vector pCR® 3.1 by a restriction 
digest, using the endonucleases BamHI and XbaI (Methods 3.2.8.2). The insert was 
isolated, purified (Methods 3.2.8.) and used as a hybridization probe for further Northern 
Blot Analyses (Figure 7). 
 
 
 
 
 
Results  55 
 
Figure 7: Isolated FGF-BP2 cDNA Fragment 
200 ng
50 ng
700 bp
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Figure 7: Isolated FGF-BP2 cDNA Fragment. The isolated FGF-BP2 fragment (50µg and 
200µg) is shown on an agarose gel next to a 1kb DNA ladder. 
 
 
4.6 Stable Transfection of the Cell Line SW-13 with the FGF-BP2 cDNA 
 
The human adrenal carcinoma cell line SW-13 was chosen for a stable transfection with 
the FGF-BP2 plasmid. SW-13 cells express high levels of FGF but lack both FGF-BP1    
(Introduction 2.6) and FGF-BP2 mRNA expression (Figure 8). The cells were transfected 
with the eukaryontic pCR® 3.1 vector containing the FGF-BP2 ORF and with an empty 
vector as a negative control (Methods 3.7). The expression in the pCR® 3.1 vector is 
driven by the CMV promoter. Earlier studies with SW-13 cells had shown that the CMV 
promoter supports high levels of gene expression in this cell line. The stably transfected 
cells were selected after G418 treatment. High levels of FGF-BP2 mRNA in the FGF-
BP2 transfectants and no FGF-BP2 signal in the mock transfected cells were detected by 
Northern Blot Analysis (Figure 8). The total RNA harvest from the FGF-BP2 transfected  
SW-13 cells was later also used as a positive control on all further Northern Blot 
Analyses to detect the FGF-BP2 mRNA expression signals. 
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Figure 8: Expression of FGF-BP2 mRNA in SW-13 transfected Cells. 
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Figure 8: Expression of FGF-BP2 mRNA in SW-13 transfected Cells. A Northern Blotting 
analysis of SW-13 transfected cells. Total RNA (20µg) derived from mock and FGF-BP2 
transfected cells were separated and probed as described in Methods 3.2.11. 
 
 
4.7 FGF-BP2 Expression in Normal Tissues and Tumor Cell Lines and Comparison 
with FGF-BP1 Expression 
 
After the significance of FGF-BP2 as a tumor promoter had been shown in soft agar 
assays it was of major interest to study the FGF-BP2 expression pattern in physiological 
and pathological conditions. Therefore, the FGF-BP2 mRNA expression in normal adult 
tissues as well as in 36 human cancer cell lines was examined by Northern Blot Analysis.  
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4.7.1. FGF-BP2 Expression in Normal Tissues 
 
Analysis of a ClonTech Multiple Tissue Northern Blot revealed an abundance of FGF-
BP2 mRNA expression in peripheral blood leukocytes, heart, spleen, liver and lung. The 
highest level was detected in blood leukocytes (Figure 9). The detected signal for liver 
appeared predominantly at a higher Mr , which is not present in other tissues. Lower FGF-
BP2 mRNA message levels were also detected in other tissues: skeletal muscle, colon, 
thymus, kidney and small intestine samples. No signal, however, could be observed in 
brain and placenta samples. 
 
 
Figure 9: Expression of FGF-BP2 mRNA in Normal Adult Tissue I 
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Figure 9: Expression of FGF-BP2 mRNA in Normal Adult Tissue I. A ClonTech Multiple 
Tissue Northern Blot was probed with the FGF-BP2 cDNA fragment 
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The distinct mRNA expression pattern of FGF-BP2 was also apparent upon analysis of a 
ClonTech RNA Master Dot Blot, which contains poly-(A) RNA samples of 50 human 
tissues (Figure 10). The Dot Blot reveals an FGF-BP2 mRNA expression in high levels in 
peripheral leukocytes and spleen, as also shown in the Multiple Tissue Northern Blot. It 
also shows a high expression level of FGF-BP2 in trachea, spinal cord and occipital lobe 
and a weaker signal in skeletal muscle, colon, bladder, pancreas, uterus, pituitary gland, 
adrenal gland, salivary gland, mammary gland, stomach, bone marrow and heart.  
 
 
Figure 10: Expression of FGF-BP2 mRNA in Normal Adult Tissue II 
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Figure 10: Expression of FGF-BP2 mRNA in Normal Adult Tissue II. A ClonTech Human 
RNA Master Blot was probed with the FGF-BP2 cDNA fragment, revealing an intense positive 
staining for peripheral leukocytes (E6), spleen (E4), spinal cord (B7), occipital lobe (B1) and 
trachea (F3). 
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4.7.2. Comparison of FGF-BP1 and FGF-BP2 Expression in Normal Tissue 
 
After stripping the FGF-BP2 signal of both blots, the membranes were reprobed with an 
FGF-BP1 ORF probe, to show the FGF-BP1 expression pattern in comparison to FGF-
BP1. On the ClonTech Multiple Tissue Northern Blot no signal for FGF-BP1 was 
detectable (data not shown), similar to previous observations (Czubayko et al., 1994). 
The ClonTech RNA Master Dot Blot though showed a distinct FGF-BP1 expression 
pattern (Figure 11). FGF-BP1 is expressed in a high level in trachea, colon and uterus. It 
shows a lower expression in pituitary gland, adrenal gland, salivary gland, stomach, 
heart, peripheral leukocytes, spleen, spinal cord and occipital lobe.  
 
 
Figure 11: Expression of FGF-BP1 mRNA in Normal Adult Tissue 
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Figure 11: Expression of FGF-BP1 mRNA in Normal Adult Tissue. A ClonTech Human 
RNA Master Blot was probed with the FGF-BP1 cDNA fragment, revealing an intense staining 
for trachea (F3), colon (C4) and uterus (C6) 
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The distribution and comparison of both FGF-BPs in the presented tissues of the 
ClonTech RNA Master Dot Blot is shown in Figure 12. The only tissue examined which 
shows high mRNA levels of both FGF-BPs is trachea. Interestingly the GAPDH-
normalized expression levels of both FGF-BPs in pituitary gland, adrenal gland, and 
salivary gland appear to have similar ratios, proportional to each other in their intensity. 
 
 
Figure 12: Distribution and Comparison of FGF-BP1 and FGF-BP2  
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Figure 12: Distribution and Comparison of FGF-BP1 and FGF-BP2 mRNA Expression.  
The distribution of FGF-BP1 (open bars) and FGF-BP2 (solid bars) mRNA in selected tissues are 
blotted. Signal intensities are assigned with arbitrary units. 
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4.7.3. FGF-BP2 Expression in Tumor Cell Lines 
 
After examining the FGF-BP2 expression under physiological conditions the next step 
was to study the expression of FGF-BP2 under pathological conditions. Therefore human 
cancer cell lines were investigated for the expression of mRNA signals of FGF-BP2. The 
expression of the FGF-BP2 mRNA was studied by Northern Blot Analysis.  
36 tumor cell lines of various tumor types were examined, including breast carcinoma 
cell lines (BT-20, BT-549, MCF-7, MDA-231, MDA-435, SK-BR-3, MDA-460, MDA-
468), colon carcinoma cell lines (LS 180, HT-29, SW480, SW680), prostate carcinoma 
cell lines (LNCaP-FGC-10, DU 145, PC-3), melanoma cell lines (1205LU, SK-MEL-5, 
SK-MEL-24, SK-MEL-31), an adrenal carcinoma cell line (SW 13), a cervical carcinoma 
cell line (ME 180), choriocarcinoma cell lines (JAR, JEG-3), pancreatic carcinoma cell 
lines (PANC-89, COLO 357), leukemia cell lines (HL-60, Jurkat, K-562), a liver cell 
carcinoma cell line (Hep G2), glioblastoma cell lines (U-87, U-138, U373, T-98, A-172, 
Hs 683) and a lung carcinoma cell line (WI-38). Also a human umbilical vein endothelial 
cell line (HU-VEC) and neonatal melonocytes were studied for their FGF-BP2 mRNA 
expression.  
Of all the probed cell lines the FGF-BP2 mRNA signal could distinctively be detected in 
all of the melanoma cell lines (Figure 13). Interestingly, a specific mRNA-binding 
running at a higher Mr was found in the liver cell carcinoma cell line Hep-G2 (Figure 13), 
somehow similar to what was observed in the liver tissue of the ClonTech Multiple 
Tissue Northern Blot (Figure 9). All other 32 cell lines were negative for FGF-BP2 
mRNA expression, including normal human neonatal melanocytes. 
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Figure 13: FGF-BP2 mRNA Expression in Tumor Cell Lines. 
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Figure 13: FGF-BP2 mRNA Expression in Tumor Cell Lines. A Northern Blotting analysis of 
tumor cell lines. Total RNA derived from tumor cell lines and lymph node tissue was separated 
and probed with the FGF-BP2 cDNA. On this blot a positive signal for FGF-BP2 mRNA is 
detectable for the Melanoma Cell Lines MEL-SK-5, MEL-SK-24, MEL-SK-31, and for the Liver 
Cell carcinoma Cell Line Hep G2, running at a higher Mr. 
 
 
4.7.4. Comparison of FGF-BP1 and FGF-BP2 Expression in Tumor Cell Lines 
 
This very distinct expression pattern of FGF-BP2 is different from what was detected 
before for FGF-BP1. In fact, FGF-BP1 shows mRNA expression in numerous tumor cell 
lines (Introduction 2.6, Table 1), including prostate carcinoma, breast carcinoma, cervix 
carcinoma, pancreatic carcinoma, lung carcinoma and colon carcinoma. Conversely the 
investigated melanoma cell lines that are positive for FGF-BP2 mRNA expression do not 
show a positive signal for FGF-BP1. As a matter of fact the expression patterns of FGF-
BP1 and FGF-BP2 are not overlapping among the cell lines studied (Table 3). 
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Table 3: FGF-BP1 and FGF-BP2 mRNA Expression in Human Cell Lines 
Cell Type Cell Line FGF-BP1 FGF-BP2 
Melanoma 1205LU,SK-MEL-5 
SK-MEL-24, SK-MEL-31 
- 
 
+ 
 
Prostate Carcinoma LNDaP-FGC-10 - - 
 DU 145, PC-3 + - 
Colon Carcinoma LS-180 + - 
 HT-29, SW480, SW680 - - 
Breast Carcinoma BT-20, MCF-7, MDA-231, 
MDA-435, SK-BR-3 
- - 
 MDA-460, MDA-468, BT-549 + - 
Adrenal Carcinoma  SW-13 - - 
Cervix Carcinoma ME 180 + - 
Choriocarcinoma JAR, JEG-3 - - 
Pancreatic Carcinoma PANC-89, COLO 357 + - 
Leukemia HL-60, Jurkat, K-562 - - 
Liver Carcinoma Hep G2 - (+)* 
Glioblastoma U-87,  U-138, U-373, T-98,  
A-172, Hs 683 
- - 
Other WI-38 (Lung Carcinoma) - - 
 HU-VEC (Human umbilical vein 
endothelial cells) 
Neonatal melanocytes 
- - 
 
 
Table 3: FGF-BP1 and FGF-BP2 mRNA Expression in Human Cell Lines. All human cell 
lines which were examined for FGF-BP2 mRNA expression by Northern blotting analysis are 
listed and compared to their expression of FGF-BP1 mRNA. 
* In the Liver Cell Carcinoma Hep G2 a higher Mr  FGF-BP2 mRNA species was distinguished. 
 
 
4.8. The Regulation of FGF-BP2 mRNA Expression by Serum and 
all-trans-retinoic Acid. 
 
As reviewed in the introduction, former studies have revealed a well-defined in vitro 
regulation of FGF-BP1 mRNA. In particular the regulation of FGF-BP1 expression by 
all-trans retinoic acid (tRA) was examined. Therefore the next step in this study was to 
answer the question if this regulation also applies for FGF-BP2. For further studies the 
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two melanoma cell lines 1205LU and SK-MEL-5 were chosen, both expressing FGF-BP2 
mRNA on a adequate level.  
 
 
4.8.1. FGF-BP2 Serum Regulation 
 
Since recently a significant upregulation of FGF-BP1 mRNA by fetal bovine serum 
(FBS) was shown (Harris et al., 2001) the initial experiment for a regulation study of the 
FGF-BP2 mRNA was the examination of FGF-BP2 serum regulation by Northern 
Blotting analyses.  
The 1205LU melanoma cells were grown in medium containing 5% FBS. Before the 
experiment the cells were washed twice with serum-free medium (Methods 3.10). 
Hereafter the cells were incubated with 5% serum medium for 3 hours, 6 hours and for 24 
hours. A control group with serum-free medium was harvested after 3 hours. The total 
RNA (20µg) of each group was separated and probed by Northern Blotting analysis. The 
FGF-BP2 mRNA signal intensities were quantified and normalized for GAPDH 
expression (Figure 14). Conversely to what was shown for FGF-BP1 in the ME-180 SCC 
cell line, the result exposed no significant up- or downregulation of FGF-BP2 mRNA in 
the 1205LU melanoma cell line when incubated with serum (Discussion 5.7). The 
experiment was repeated with different time points of harvesting (2 hours, 5 hours, 20 
hours), revealing the same results (data not shown). The effect of serum-containing 
medium in contrast to serum-free medium was also studied in the MEL-SK-5 melanoma 
cell line, displaying the same result (data not shown). 
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Figure 14: Fetal Bovine Serum Treatment of 1205LU Melanoma Cells 
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Figure 14: Fetal Bovine Serum Treatment of 1205LU Melanoma Cells. Northern blotting 
analysis of the expression of FGF-BP2 mRNA in the 1205LU cell line incubated with serum 
containing medium compared to the FGF-BP2 mRNA expression of a serum-starved control 
group. Cells were harvested at 3 different time points after serum exposure. Signal intensities 
were quantified by phosphoimaging and normalized for GAPDH. The results are presented in 
percentage of the control group. The experiment was carried out in triplicates of each group. 
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4.8.2 FGF-BP2 Regulation by all-trans Retinoic Acid (tRA) 
 
As described in the Introduction section FGF-BP1 mRNA shows a very clear 
downregulation induced by all-trans-retinoic acid (tRA). FGF-BP1 downregulation in the 
SCC cell line ME-180 was most significant in the first 6 hours after tRA exposure and 
remained constant in the continuous presence of tRA for another 24 hours. The maximum 
effect was reached with a tRA concentration of 10-5 M.  
Initially the effect of tRA on the FGF-BP2 mRNA expressing 1205LU melanoma cell 
line was tested at two different time points, 5 hours and 20 hours after exposure. The tRA 
concentration was chosen to be 10-5 M, similar to what was known from the regulation of 
FGF-BP1. Control groups were harvested either after 5 hours or 20 hours. Since tRA is 
solubilized in 0.1% DMSO, the same amount of DMSO was added to the control groups 
to exclude a possible effect of the vehicle.  
In contrast to the tRA effect on the ME-180 cell line, no major effect of tRA on the 1205 
cells was detectable (Figure 15). A slight decrease in the FGF-BP2 mRNA in the tRA 
treated cells appears to be within the range of the standard deviation and therefore does 
not seem to be significant. The effect of tRA was also tested in the MEL-SK-5 melanoma 
cell line after an exposure time of 5 hours. Here as well no significant effect of tRA on 
the FGF-BP2 mRNA was measurable (Figure 15).  
During this series of experiments, the effect of TPA, EGF and FGF on the mRNA 
expression of FGF-BP2 was tested in both cell lines and at various time points. No 
significant or consistent effect of either of the compounds was detectable (Discussion 
5.8). 
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Figure 15: tRA Treatment of 1205LU and MEL-SK-5 Melanoma Cells 
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Figure 15: tRA Treatment of 1205LU and MEL-SK-5 Melanoma Cells. Northern blotting 
analysis of the tRA effect on 1205LU and MEL-SK-5 melanoma cells after exposure to tRA in a 
concentration of 10-5M. 1205LU cells were harvested after an exposure time of 5 and 20 hours. 
MEL-SK-5 cells were harvested after tRA exposure of 5 hours. Signal intensities were quantified 
by phosphoimaging and normalized to GAPDH. The results are presented in percentage of a tRA 
untreated control group. The experiment was carried out in triplicates of each group. 
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Since the tRA effect on the expression of FGF-BP1 mRNA was described to be most 
significant in early hours after exposure (Liaudet-Coopman and Welllstein, 1996) the 
next step to precise these preliminary data was to particularly study the time course of the 
tRA effect in early time points. These experiments were completed in both melanoma cell 
lines and, with regard to the possibility of a posttranscriptional regulation as described for 
the ME-180 cells, also in the transfected SW-13 cell line (Figures 16,17,18). 
The 1205LU melanoma cells were exposed to tRA in concentrations of 10-5 M and 10-7 M 
for ½ hour, 1 hour, 2 hours, 3 hours, and 5 hours before harvesting the RNA. The cells of 
the tRA untreated control group (0.1% DMSO) were harvested after ½ hour, 3 hours and 
5 hours (Figure 16).  
In the first experiment a minor upregulation of the FGF-BP2 mRNA appears to become 
visible after tRA exposure of 2 hours in a concentration of 10-7 M. All other groups show 
only slight variations of their signal intensity, almost within the range of the standard 
deviation of the control groups. In the second experiment, which was performed under 
the exact same conditions again no significant effect of tRA in time of its exposure was 
measurable (Figure 16). All variations of signal intensity are within the standard 
deviation and show no statistically significant effect. No effect of tRA on the amount of 
mRNA expression of FGF-BP2 in the melanoma cell line 1205LU was detectable by 
Northern Blotting analysis. 
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Figure 16: Time Course of tRA Treatment of 1205LU Melanoma Cells 
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Figure 16: Time Course of tRA Treatment of 1205LU Melanoma Cells. Northern blotting 
analysis of the tRA effect on 1205LU melanoma cells after exposure to tRA in concentrations of 
10-5 M and 10-7 M in time. RNA of the treated cells was collected after an exposure time of ½ 
hour, 1 hour, 2 hours, 3 hours, and 6 hours. Untreated cells were harvested after ½ hour, 2 hours 
and 5 hours. RNA signal intensities were quantified by phosphoimaging and normalized to 
GAPDH. The results are presented in percentage of the tRA untreated control group harvested 
after ½ hour. The experiment was carried out in triplicates of each group. 
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Figure 17: Time Course of tRA Treatment of MEL-SK-5 Melanoma Cells 
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 Figure 17: Time Course of tRA Treatment of MEL-SK-5 Melanoma Cells. Northern Blotting 
analysis of the tRA effect on MEL-SK-5 cells after exposure to tRA in concentrations of 10-5 M 
and 10-7 M in time. In the first experiment treated cells were harvested after an exposure time of 
½ hour, 1 hour, 2 hours, 3 hours, and 6 hours. Untreated cells were harvested after ½ hour, 2 
hours and 5 hours. In the second experiment RNA of the treated cells was collected after 1 hour, 2 
hours and 3 hours. Control groups were harvested after 1 hour and after 3 hours. Signal intensities 
were quantified by phosphoimaging and normalized to GAPDH. The results are presented in 
percentage of the tRA untreated control group harvested at the first time point. The first 
experiment was carried out in duplicates of each group, the second one in quadruplicates. 
 
Results  71 
 
In the MEL-SK5 cell line the first time course experiment was completed under exactly 
the same conditions as the 1205LU time course experiments. Again no major signal 
intensity changes were measurable among the treated groups. All minor changes were 
more or less within the range of the standard deviation of the control groups. However, 
the 10-5 M tRA treated group appeared to be with a slight signal decrease compared to the 
control groups. In order to confirm a possible effect a second time course experiment 
with the MEL-SK-5 cell line was performed. RNA of 10-5 M tRA treated and untreated 
(DMSO) cells was collected after 1 hour, 2 hours and 3 hours (Figure 17). This time 
clearly no effect of tRA was visible. It seems that there is no tRA effect on the mRNA 
expression of FGF-BP2 in the MEL-SK-5 cell line as detectable by Northern blotting 
analysis. 
Since in the ME-180 cell line a posttranscriptional downregulation of the FGF-BP1 
mRNA is described a final time course tRA experiment was done with the FGF-BP2 
transfected SW-13 cells. The expression vector pCR® 3.1 is driven by the CMV 
promoter. The 10-5 M tRA treated cells were harvested after 1, 2, and 3 hours of 
treatment. The DMSO treated control groups were harvested after 1 and 3 hours (Figure 
18). Once again it was not possible to show an effect of tRA on the RNA expression of 
FGF-BP2. 
Finally, to verify that adequate concentrations of tRA were used, a dose response 
experiment was completed. MEL-SK-5 cells were treated with tRA concentrations of -
log[9], -log[8], -log [7], -log [6], and -log [5]. RNA from all cells, including an untreated 
control group was collected after 2 hours (Figure 19). The result reveals that there is no 
dose dependent effect of tRA on the FGF-BP2 mRNA in MEL-SK-5 melanoma cells. 
Overall speaking it seems obvious that in both studied melanoma cell lines it was 
impossible to show an effect of tRA or fetal bovine serum treatment on the expression of 
FGF-BP2 mRNA. Also no posttranscriptional regulation mechanisms in the FGF-BP2 
transfected adrenal carcinoma cell line SW-13 were detectable whatsoever by 
quantification of Northern Blotting signals (Discussion 5.8).  
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Figure 18: Time Course of tRA Treatment of FGF-BP2 transfected SW-13 Cells 
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Figure 18: Time Course of tRA Treatment of FGF-BP2-transfected SW-13 Cells. Northern 
blotting analysis of the tRA effect on FGF-BP2-transfected SW-13 cells after exposure to tRA in 
a concentration of 10-5M and in time. The total RNA of the treated cells was collected after 1 
hour, 2 hours and 3 hours of exposure time. Control groups were harvested after 1 and 3 hours. 
The total RNA was separated and probed. Signal intensities were quantified by phosphoimaging 
and normalized to GAPDH. The results are presented in percentage of the tRA untreated control 
group harvested at 1 hour. The experiment was carried out in triplicates of each group. 
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Figure 19: Dose Response of tRA Treatment of MEL-SK-5 Cells 
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Figure 19: Dose Response of tRA treatment of MEL-SK5 cells. Northern blotting analysis of 
tRA effect on the FGF-BP2 mRNA expression under different concentrations. Cells were 
exposed to tRA in concentrations of -log [9], -log [8], -log [7], -log [6], and -log [5]. All cells 
including a tRA free control group were harvested after 2 hours. Their total RNA was separated 
and probed with the FGF-BP2 cDNA. Signal intensities were quantified by phosphoimaging and 
normalized to GAPDH. The results are presented in percentage of the tRA untreated control 
group harvested at 1 hour. The experiment was carried out in triplicates of each group. 
 
 
4.9 Biological activity of FGF-BP2 transfected SW-13 Cells in Soft Agar Assays 
 
To examine the potential role of FGF-BP2 in tumor growth, the FGF-BP2 transfected 
SW-13 cell line was selected as a model system. The wild type SW-13 cell line is 
tumorigenic but does not form colonies in soft agar, nor does it form tumors in athymic 
nude mice unless the cells are supplemented with exogenous FGFs or transfected with 
FGF genes with secreted signal peptides (Czubayko et al., 1994, Wellstein et al., 1990). 
The cells transfected with the empty pCR ® 3.1 vector were used as a negative control. 
The transfected cells were plated on agarose dishes and incubated for 10-14 days 
(Methods 3.8). 
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Figure 20: Biological Activity of in SW-13 FGF-BP2 transfected Cells 
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Figure 20: Biological Activity of in SW-13 FGF-BP2 transfected Cells. Colony formation in 
soft agar by FGF-BP2 transfectants (dashed line) and by control mock transfected cells (solid 
line) in the presence of various concentrations of free exogenous bFGF or aFGF. A circle 
indicates treatment of FGF-BP2 transfected cells with a neutralizing monoclonal antibody against 
bFGF (1µg/ml). 
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Hereafter, the number of colonies of 40 - 60µm in diameter were counted. The results 
revealed that twice as many colonies were formed in soft agar by FGF-BP2 transfectants 
as compared to the mock transfected cells (Figure 20), indicating that FGF-BP2 promotes 
colony formation. However, both transfected cell populations were stimulated to form 
more colonies in presence of exogenous bFGF (FGF-2), but consistently twice as many 
colonies could be observed to be formed by the FGF-BP2 transfectants relative to the 
control cells at low exogenous bFGF concentrations (0.05 – 0.10 ng/ml). At high 
exogenous bFGF concentrations (> 0.25 ng/ml) the detected difference of the two cell 
populations greatly diminished. In one experiment an bFGF antibody was added to the 
FGF-BP2 transfected cells. In the presence of 1ng/ml bFGF, treatment with an α-bFGF 
antibody (1µg/ml) effectively reduced colony formation in FGF-BP2 transfectants to 
levels comparable to untreated mock transfected cells. Similar observations concerning 
colony formation induced by FGF-BP2 transfectants were made when exogenous aFGF 
(FGF-1) was used instead of bFGF, although higher aFGF concentrations were required. 
Treatment with an α-bFGF antibody (1µg/ml) had no apparent effect on colony 
formation for FGF-BP2 transfected cells in the presence of 0.1 ng/ml of aFGF, indicating 
the specificity of the antibody used. 
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       5. DISCUSSION 
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5.1 Genomic Sequence analysis of FGF-BPs 
 
In this study the gene structure, tumorigenic activity, expression profile and in vitro 
mRNA regulation by serum and retinoids of a novel fibroblast growth factor binding 
protein (FGF-BP2) was examined. In the beginning of the study little was known about 
the gene and the protein that was later named FGF-BP2. A gene bank BLAST search on 
the basis of the FGF-BP1 cDNA sequence published by Wu et al. (Wu et al., 1991) 
revealed the homology of this gene to FGF-BP1. By performing sequence similarity 
searches we were able to map both cDNA sequences of human FGF-BP1 and FGF-BP2 
on a chromosome 4 genomic fragment of 91.5 kb in length. On the basis of this genomic 
sequence and other related sequences available in the GenBank data base, the gene 
structures for both FGF-BPs are deduced as shown in Figure 4.  
Since the promoter region of FGF-BP2 has not been defined, one can not preclude the 
possibility that the FGF-BP2 gene may contain another exon encoding for its 5’-
untranslated region. Apparently the 200 bp region immediately 5’ upstream of the 
putative transcription start site of the FGF-BP2 gene does not contain any TATA box or 
homologous regulatory elements such as Ets, AP-1, SP1 and CAATT/enhancer binding 
protein C/ERP sites which is in contrast to the human FGF-BP1 promoter (Harris et al., 
1998). This already suggests that the two FGF-BP genes may be regulated by different 
mechanisms, which was furthermore shown in this study for the regulation of FGF-BP2 
by serum and retinoids in contrast to the known mechanisms for FGF-BP1.  
 
 
5.2 Biochemical Characterization of Recombinant Human FGF-BP2 
 
Parallel to this study, Dr. Q. Nguyen performed further experiments revealing additional 
data that are relevant to this discussion. 
Ogawa et al., the first to publish data on this novel protein (Introduction 1.5, Ogawa et 
al., 2001), affirm that FGF-BP2 would not show direct association with 125I-labeled  
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recombinant human basic FGF and therefore, besides all biochemical similarity see no 
functional association with FGF-BP1.  
In contrast to these findings Nguyen was able to demonstrate that actually FGF-BP2 is 
capable of binding FGF-2 and heparin. First of all he constructed and expressed FGF-
BP2 containing a Myc/His tag at its carboxyl terminus in the model of stable transfected 
SW-13 cells. Proteins in serum-free culture media of FGF-BP2/Myc/His or mock 
transfectants were incubated with Ni-NTA resins, then subjected to immunoblotting 
analysis using a monoclonal antibody specific for the His tag. A reactive band of Mr  38 
kDa was only observed for samples of FGF-BP2/Myc/his transfected cells (Q. Nguyen 
and A. Wellstein, unpublished data). A similar reactive band was detected on the blots 
that were probed separately with polyclonal antibodies raised against FGF-BP2 peptides 
whose sequence is shown in Figure 3. This finding is somewhat comparable to the data 
from Ogawa et al, who detected FGF-BP2 in a 37 kDa form secreted by transfected COS-
7 cell line and also by Th-1 cells. The transfected COS-7 cell line also retained a major 
28 kDa form, which the authors claim to be identical in size with an in vitro 
transcription/translation product, and also a minor 37 kDa form. From their findings the 
authors suggest that FGF-BP2 is synthesized as a polypeptide with an apparent molecular 
mass of 28 kDa then modified and secreted into the extracellular space as a 37 kDa form 
(Introduction 1.5; Ogawa et al., 2001). However, in Dr. Nguyen’s work it appeared as if 
the recombinant FGF-BP2 is secreted into the supernatant as a dimer. Upon incubation of 
the samples with Ni-NTA resins in the presence of 125I-FGF-2, in addition to the 
immunoreactive band, a strong radiolabeled band of Mr 17 kDa was detected in samples 
of FGF-BP2 transfectants, whereas a faint radioactive band was observed for mock 
control samples (Q. Nguyen and A. Wellstein, unpublished data). These data demonstrate 
that FGF-BP2 can interact with FGF-2 (bFGF). An immunoreactive band of Mr  38 kDa 
was also detected for FGF-BP2/Myc/His samples eluted from heparin-Sepharose beads, 
indicating that FGF-BP2 is a heparin binding protein (Q. Nguyen and A. Wellstein, 
unpublished data). 
 The deduced amino acid sequence of FGF-BP2, as shown before, suggests a 
secreted protein with a Mr of about 22 kDa without the putative signal peptide.  
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Surprisingly these data reveal that in the supernatant of the FGF-BP2 transfected SW-13 
cells predominantly a 38 kDa protein is present that is reactive to anti-His/Myc tag 
monoclonal antibodies and anti-FGF-BP2 peptide polyclonal antibodies. In vitro coupled 
transcription/translation reactions of the expression plasmid containing the open reading 
frame of FGF-BP2 also yielded a radioactive band of similar molecular weight (Q. 
Nguyen and A. Wellstein, unpublished data). Based on the apparent molecular weight 
difference, one can assume that that this is the dimeric form of FGF-BP2. Interestingly, 
this association of FGF-BP2 monomers is covalently linked and not mediated through 
cysteine residues. In the future the biochemical nature of this dimer is to investigate and 
furthermore it is to determine if the dimeric form of FGF-BP2 is essential for FGF-2 
interaction and for its tumor promoting properties. 
 
 
5.3 FGF-BP2 induced Tumor Growth in Athymic Nude Mice 
 
For further discussion of the results of this study it seems necessary to review additional 
data on FGF-BP2, also obtained in the meantime by Q. Nguyen. The FGF-BP2 
transfected human adrenal cell carcinoma cell line SW-13 that was used for the soft agar 
assay was also utilized for an animal study with athymic nude mice. Besides the fact that 
wild type SW-13 cells do not form colonies in soft agar, it was also shown that they do 
not form tumors in athymic nude mice, unless they are supplemented with exogenous 
FGFs or transfected with FGF genes with secreted signal peptides (Wellstein et al., 
1990). It was previously demonstrated that overexpression of the FGF-BP1 gene in the 
SW-13 cell line does not only induce these cells to grow colonies in soft agar, but also to 
form highly vascularized tumors in athymic nude mice (Czubayko et al. 1994). In a 
similar experiment FGF-BP2- and empty vector- transfected SW-13 cells were injected 
subcutaneously in female athymic nude mice, with three animals per treatment. The 
animals were observed for at least eight weeks for tumor formation. The tumor sizes were 
estimated from the product of the perpendicular diameters of the tumors and after the 
mice were sacrificed, the tumors were extracted for total RNA for FGF-BP2 expression  
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analysis. The results from this experiment revealed that tumors had grown in all three 
animals injected with FGF-BP2 transfected cells while animals injected with mock 
transfected cells were tumor free, indicating that FGF-BP2 supports tumor growth in 
vivo. Northern Blotting analysis showed that cells in all excised tumors expressed high 
mRNA levels of FGF-BP2. Once again the thesis of secreted FGF-BP2 solubilizing 
bFGF deposited by the tumor cells and/or locally stored FGFs in the stromal tissue seems 
verified in these tumor studies in vivo, demonstrated for the FGF-BP2 transfected SW-13 
cells in this case. 
This data again seems to be consistent with the concept that secreted FGF-BP2, just like 
it is proposed for FGF-BP1, can recover bFGF from its immobilized state on the cell 
surface and thus serve as an extracellular carrier molecule to its receptor. But still the 
alternative approach of FGF-BP2 preventing the binding of bFGF to matix proteoglycans 
can not be ruled out. However, in any case it appears that also FGF-BP2 can bolster 
autocrine and paracrine activities of bFGF in vitro and in vivo. 
 
 
5.4 FGF-BP2 Expression in Normal Tissue and in Tumor Cell Lines 
 
The above data support the notion that expression of FGF-BP2 in SW-13 cells can render 
their inactive bFGF into an autocrine- and paracrine-acting factor that supports tumor 
growth and angiogenesis. To assess the significance of FGF-BP2 expression for human 
physiology or pathology, FGF-BP2 mRNA in normal adult tissues and tumor cell lines 
was assayed by Northern Blotting analysis. The analysis of a ClonTech Multiple Tissue 
Northern Blot and a ClonTech Human RNA Master Blot probed with the FGF-BP2 
cDNA fragment revealed a noticeable expression pattern of this novel FGF-binding 
protein in normal human tissue as presented in Results 4.7.1, Figure 9 and 10. In the 
ClonTech Multiple Tissue Northern Blot (Figure 9) the strong expression of the FGF-
BP2 mRNA message in peripheral leukocytes, heart, spleen and lung was striking. 
Interestingly a signal detected for liver appeared predominantly at a higher Mr , that was 
not present in other tissues. Instead of the 1.3 kb FGF-BP2 message that is present in the  
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other positive samples a distinct 1.8 kb message is visible. This peculiar mRNA signal at 
a higher Mr , which was accordingly also detected in the liver carcinoma HepG2 cell line, 
may be due to alternative splicing. A possible thesis is that the 1.8 kb species is a product 
of a differential transcription start site or a poly-(A) termination site.  
The fact that the strongest FGF-BP2 mRNA signal was observed in peripheral leukocytes 
confirms the findings of Ogawa et al.(Ogawa et al., 2001, Introduction 1.5) who found a 
protein named Ksp37, which is identical to FGF-BP2, as a novel serum protein produced 
by cytotoxic lymphocytes. From all peripheral blood leukocytes the authors found FGF-
BP2 expression limited to Th1-type CD4+ T cells, effector CD8+ T cells, γδ T cells and 
CD16+ NK cells. Besides a number of FGF-BP2 negative tumor cell lines (see below) 
obviously no other normal adult tissue was analyzed in this study and therefore the 
authors draw the conclusion that FGF-BP2 is tightly regulated and selectively produced 
by cytotoxic lymphocytes. However, from the findings in this study it appears to be 
correct that FGF-BP2 mRNA has a distinct and tight expression pattern within tumor cell 
lines, where it is almost exclusively expressed by melanoma cell lines, besides a different 
species in the HepG2 liver carcinoma cell line (Results 4.7.3, Figure 13), but it is 
obviously incorrect that FGF-BP2 is selectively produced by cytotoxic lymphocytes.  
Furthermore the examined RNA Blot, the ClonTech RNA Master Dot Blot exposed 
findings that are corresponding to what was seen within the Multiple Tissue Northern 
Blot. Again an intense positive staining for peripheral leukocytes and spleen was visible, 
but also for spinal cord, occipital lobe and trachea, besides many other tissues with a 
weaker signal (Figure 10). The significance of the widespread FGF-BP2 message in these 
tissues of whatever origin is nonetheless unknown at the moment.  
In contrast the expression pattern of the FGF-BP2 mRNA in tumor cell lines does not 
show such a wide-ranging expression pattern at all. In fact the FGF-BP2 mRNA 
expression from all 37 cell lines of various tumor types is limited to all of the melanoma 
cell lines and the liver carcinoma cell line HepG2. Correspondingly to these findings 
Ogawa et al also failed to detect the FGF-BP2 message in any tumor cell line examined 
in their study. The cell lines scanned in their survey included Jurkat, Molt-4, MT-2, TL-
Mor, CCRF-CEM, Daudi, LCL-Nag, U937, K562, HEL, HeLa and also HepG2. It is not  
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reported whether a somewhat different signal was detected in the liver carcinoma cell line 
or not.  
Basically it is striking that while the FGF-BP2 mRNA signal is present frequently in 
normal adult tissue in contrast it shows a restrictive and distinct expression under 
pathological conditions. Moreover most interesting is the fact that FGF-BP2 is expressed 
in all examined melanoma cell lines while no message was detectable in normal human 
neonatal melanocytes, indicating that the expression of the gene is initiated during 
premalignant or malignant stages in the process of skin carcinogenesis. It is well 
established that bFGF is a potent mitogen and required for human melanocytes in cell 
culture (Coleman and Lugo, 1998). Matching to what this study revealed for FGF-BP2 it 
was previously shown that in contrast to normal human melanocytes which do not 
express bFGF, abundant bFGF messages are detected in all melanoma tumors and most 
cell lines derived from metastatic melanomas (Reed et al., 1994, albino et al., 1991). In 
addition, inhibition of bFGF or its receptor FGFR-1 synthesis in melanoma cell lines by 
antisense oligonucleotides leads to the suppression of tumor growth in vitro and in vivo 
(Becker et al., 1998, Wang et al., 1997). These studies suggest that bFGF and its 
activated signal pathway play a crucial role in the development of melanoma. Together 
with this evidence and the here displayed analogous expression pattern of FGF-BP2 one 
can suggest that FGF-BP2 is a tumor promoting agent by solubilizing matrix bound 
bFGF and therefore it is likely that FGF-BP2 may play an important role in melanoma 
progression and skin carcinogenesis. 
 
 
5.5 Comparison of FGF-BP1 and FGF-BP2 Expression in Normal Tissue  
and in Tumor Cell Lines. 
 
The expression of FGF-BP1 under physiological and pathological conditions has been 
evaluated previously (Czubayko et al., 1994, Tuveson, 1998). Nevertheless in this study 
the two commercially available blots that where probed with the FGF-BP2 cDNA probe 
were all the same again probed with the FGF-BP1 cDNA fragment, in order to have  
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comparable conditions for a comparison of the quantity of the detected messages for both 
proteins. Concerning the expression pattern of FGF-BP1 the results revealed a more or 
less consistent outcome with what was described before ( Introduction 1.6, Czubayko et 
al., 1994, Tuveson, 1998). Again it was not possible to detect FGF-BP1 signals on a 
tissue Northern Blot (Results 4.7.2, Czubayko et al. 1994), though it was possible to 
detect the FGF-BP1 message on the RNA Dot Blot (Results 4.7.2, Figure 11). Similar to 
what was shown before (Introduction 1.6, Tuveson, 1998) high levels of FGF-BP1 
mRNA were found in trachea, colon and uterus and a somewhat lower expression in 
various other tissues. In Figure 12 the distribution of FGF-BP1 and FGF-BP2 is assigned 
and also the quantity of their signal intensities is presented. On the whole it is obvious 
that the FGF-BP2 is expression is not only more intense than the expression of FGF-BP1 
but also more distributed (Figures 9,10,11,12, Table 3). On the other hand the expression 
of FGF-BP1 seems highly regulated and tissue specific, at least under physiological 
conditions. The only tissue that expresses high levels of both FGF-BPs appears to be 
trachea, while the expression levels of the two FGF-BPs in other tissues are diverse in 
their intensity. But interestingly in some tissues, e.g. pituitary gland, adrenal gland and 
salivatory gland, the expression levels appear to be somewhat proportional to each other 
(Figure 12). This may indicate that in gland tissues the two FGF-BPs undergo similar 
regulation mechanisms. Apparently the expression of FGF-BP2 is particularly intense in 
tissues of the central nervous system as in a sample from the occipital lobe and from the 
spinal cord, and also in tissues connected to the immune system, as spleen. The strong 
expression in spleen, though may be due to an intense presence of leukocytes, namely 
TH-1 lymphocytes in this organ. In these tissues with prominent FGF-BP2 appearance 
the FGF-BP1 message is at its lowest. On the other hand in the tissues with strong 
expression of FGDF-BP1, as colon and uterus, the FGF-BP2 signal is notably weak. This 
again might be an indicator for a reciprocal expression of two proteins with similar or at 
least analogous function. Finally in the RNA Dot Blot it was possible to show an 
expression of FGF-BP1 in neuroectodermal-derived tissues, as in occipital lobe, although 
with a faint signal (Figure 11). So far it was believed, that the FGF-BP1 expression 
would be restricted to neuroectodermal tissues.  
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Concerning the expression patterns of the FGF-binding proteins within tumor cell lines 
we almost find a reverse setting. Under the pathological conditions in tumor cell lines this 
study was able to show that the FGF-BP2 mRNA signal is limited to all tested melanoma 
cell lines and possibly also to a liver carcinoma cell line. The FGF-BP1 expression, 
although as well highly regulated and tissue specific is positive in more cancer cell lines 
of different origins (Introduction 1.6, Table 1, Czubayko et al., 1994, Tuveson, 1998). 
The FGF-BP1 mRNA signal was tested positive in colonic adenocarcinoma cell lines and 
in tumor samples from colon cancer patients (Tuveson 1998), as well as in breast 
carcinoma cell lines and tumor tissues. Most importantly though many squamous cell 
carcinoma cell lines derived from different origins show a positive signal for FGF-BP1 
expression. These squamous cell carcinomas include tumors of the lung, bladder, cervix 
and also skin. While the functional significance of FGF-BP1 expression in breast-, colon- 
and cervix carcinoma has been discussed elsewhere, with the new evidence of this study 
concerning FGF-BP2 the role of the FGF binding proteins in skin carcinogenesis shall be 
evaluated again (Discussion 5.6). 
 
 
5.6 Skin Carcinogenesis and Expression of FGF-BP2 in Human Melanoma Tissue 
 
The role of FGF-BP1 in skin carcinogenesis has been discussed extensively in the 
introduction to this study (Introduction 1.7, Kurtz et al., 1997, Aigner et al, in review), 
where it was reviewed that both in the mouse as well as in the human, FGF-BP1 is 
thought to play a crucial role in the early stages of skin squamous cell carcinoma. Kurtz 
et al. were able to show that in the developing skin of the mouse FGF-BP1 expression 
starts at embryonic day 9, reaches peak levels perinatally and is downregulated during 
postnatal development. Furthermore FGF-BP1 expression in the adult skin is 
dramatically increased early stages of carcinogen-induced transformation by TPA in vivo 
and by ras-activation in vitro (Kurtz et al., 1997). Using in situ hybridization techniques, 
the authors were able to show precisely the site of FGF-BP1 expression in the skin, 
namely in staged mouse embryos and TPA induced skin carcinoma samples. Later,  
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Aigner et al. were able to show similar findings in human skin cancer and wound healing, 
also using in situ hybridization to localize the FGF-BP1 activation precisely (Aigner et 
al., submitted).  
After detection of restricted FGF-BP2 expression in melanoma tumor cell lines, FGF-
BP2 expression in situ was analyzed Dr. Rafael Cabal-Manzano examined several 
melanoma tumor samples by in situ hybridization for their expression of FGF-BP2. In 
that study cryostat sections of representative melanoma tissues, obtained from the 
Lombardi Cancer Center Histopathology and Tissue shared Resource Core Facility, were 
hybridized with a sense and antisense digoxigenin labeled riboprobe of the FGF-BP2 
BamH1-Xba1 fragment containing the complete coding region. The signal was detected 
using alkaline phosphatase conjugated-sheep-anti-digoxigenin antibodies with 
BCIP/NBT (bromchlor-indolyl-phosphate/nitroblue tetrazolium) as a substrate. FGF-BP2 
and mock transfected SW-13 cells were used for positive and negative control, 
respectively. The FGF-BP2 signal was detected predominantly in the cytoplasm of FGF-
BP2 transfected cells with the antisense riboprobe, whereas no signal was detected in 
FGF-BP2 transfected cells probed with the sense riboprobe, or empty vector transfectants 
with either riboprobe, indicating the specifity of the FGF-BP2 probe (R. Cabal-Manzano 
and A. Wellstein unpublished data). In the melanoma tumor tissues, abundant expression 
of the FGF-BP2 signal were observed. An intense FGF-BP2 signal was detected mainly 
in melanoma cells using the antisense riboprobe (R. Cabal-Manzano and A. Wellstein 
unpublished data). This data, showing the FGF-BP2 molecule to be localized in situ of 
human skin cancer, strongly strengthens the hypothesis that FGF-BP2 may play a role in 
the development of melanoma growth and metastasis. 
 
 
5.7 The in vitro Regulation of FGF-BP2 by Fetal Bovine Serum, EGF and TPA 
 
As discussed in the introduction of this thesis the expression of FGF-BP1 is known to be 
regulated by several drugs and growth factors. These agents include mitogenic substances 
as the phorbol ester TPA, the growth factor EGF and also fetal bovine serum (FBS) that  
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have an inductive effect on the FGF-BP1 expression (Introduction 1.8, Harris et al., 2001, 
Harris et al, 2000(a) Harris et al, 2000(b)), and on the other hand the agent all-trans 
retinoic acid (tRA) has been shown to down-regulate the FGF-BP1 mRNA (Introduction 
1.9, Liaudet-Coopman and Wellstein, 1996, Liaudet-Coopman et al., 1997). Whereas in 
these former studies the regulative mechanisms of FBS and tRA where shown for a SCC 
cell line of the cervix, the upregulation of the FGF-BP1 mRNA by TPA was detected also 
in skin carcinogenesis, as described above.  
Taking into consideration, the so far detected analogies of FGF-BP2 and FGF-
BP1 it was only reasonable to evaluate whether similar regulative mechanisms would be 
noticeable for the novel binding protein for FGF. For this purpose two melanoma cell 
lines (1205LU and SK-MEL5) both expressing sufficient levels of the FGF-BP2 mRNA 
and also the FGF-BP2 transfected adrenal cell carcinoma cell line SW-13 were chosen. 
The SW-13 cell line, overexpressing the FGF-BP2 signal was chosen to evaluate possible 
posttranscriptional regulation mechanisms. The Northern Blotting experiments in this 
study did not reveal a significant and/or consistent mechanism for either the regulation of 
the FGF-BP2 mRNA signal by EGF or TPA (data not shown) or by Fetal Bovine Serum 
(Results 4.8.1, Figure 14). In numerous experiments with the three agents it was 
impossible to bare any remarkable change of expression of the protein’s mRNA signal, as 
detected previously for FGF-BP1, where a fourfold induction of the FGF-BP1 signal by 
EGF and also by FBS was displayed. The experiments were carried out under various 
conditions, analogous and different to the settings with FGF-BP1. They were completed 
in the presence and absence of FBS and in combination with EGF, as well as at different 
time points of harvesting and also with any reasonable concentration of the drug or 
growth factor. However, this study failed to expose any distinct in vitro regulation of the 
FGF-BP2 mRNA by any of the known inductive substances for FGF-BP1. Particularly 
remarkable was the fact that that the phorbol esther TPA did not show any effect on the 
FGF-BP2 expression signal, since its previously described inductive function was 
exceptionally evident in skin carcinogenesis. In addition it was checked if bFGF itself 
would have an effect of the expression of its binding protein. Again no significant or 
consistent result could be obtained (data not shown).  
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From these data I conclude that besides the discovered similarity of the two FGF binding 
proteins, the mechanisms for their regulation in vitro must be somehow diverse, at least 
in these different cell lines. Since there is no cell line detected that expresses both FGF-
BP1 und FGF-BP2 a direct comparison and conclusions from that are impossible. From 
what is known about the in vitro regulation of FGF-BP1 by FBS, TPA and EGF one can 
presume that none of the known activation pathways for FGF-BP1 in the ME-180 
squamous cell carcinoma cell line, as there are PKC, ERK kinase (MEK) and p38 MAP 
kinase, is activated by FGF-BP2 in a similar way for a transcriptional regulation of the 
gene in the melanoma cell lines. However, it is important to know that these two 
analogous binding proteins undergo different regulative pathways. Whatever mechanisms 
there are to up-regulate the FGF-BP2 expression remains unclear. Nevertheless, we know 
that there must be an initiation for the expression of the protein, at least in melanocytes 
that progress into melanoma cells and from this conclusion one can hypothesize that the 
initiation process of factors that are able to activate latent FGFs seems to be even more 
complex as known so far. Taking the potential relevance of FGF-BP2 for melanoma 
progression into account it seems to be important to find an answer to the question what 
the regulative mechanisms for this novel protein are, if not the ones that affect FGF-BP1. 
 
 
5.10 The in vitro Regulation of FGF-BP2 by all-trans Retinoic Acid 
 
Finally a potential downregulation of the gene expression of FGF-BP2 by retinoic acid 
was evaluated. All-trans retinoic acid (tRA) has been shown to inhibit growth and 
aberrant reverse differentiation of squamous cell carcinomas and, furthermore, FGF-BP1 
has been found to be a target for down-regulation by retinoids (Introduction 1.9, Liaudet-
Coopman and Wellstein, 1996, Liaudet-Coopman et al., 1997). In fact Liaudet-Coopman 
et al. found six different human squamous cell carcinoma cell lines to be down-regulated 
by tRA by 39-89% within 24 hours. The authors were able to prove that retinoic acid 
down-regulates FGF-BP1 mRNA in a time- and dose-dependent manner, as well as well 
as that the effect of tRA was reversible and FGF-BP1 mRNA returned to control levels  
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within 24 hours after removal of tRA (Introduction 1.9). Liaudet-Coopman et al. were 
able to present that the mRNA down-regulation of FGF-BP1 by tRA was due to a 
combination of transcriptional and post-transcriptional mechanisms. In a following study 
of Liaudet-Coopman et al., the authors revealed that tRA treatment not only reduces 
FGF-BP1 expression in vitro, but also in vivo, as demonstrated in cervical squamous cell 
carcinoma xenografts in athymic nude mice (Liaudet-Coopman et al., 1997). It was 
shown that in vivo tRA treatment not only reduced the FGF-BP expression in the 
xenografts but also inhibited angiogenesis, induced apoptosis of the tumor cells and lead 
to a decrease of the tumor growth rate.  
Taking these details into account it was reasonable to evaluate whether similar findings 
would come to pass for FGF-BP2. Consequently, as described above (Results 4.8.2) a 
series of experiments was carried out to assess a potential regulative effect of the drug. 
Corresponding to the settings from the FGF-BP1 tRA study (Liaudet-Coopman and 
Wellstein, 1996) both melanoma cell lines and also the FGF-BP2 transfected SW-13 cell 
line were analyzed in various experimental settings, as most of them are described in the 
results. However, this study could not reproduce the effect of tRA on FGF-BP1 for FGF-
BP2. Neither various time-course trials (Results 4.8.2, Figures 15,16, 17), nor a dose-
response experiment (Results 4.8.2 Figure 19) with tRA achieved to reveal any 
significant and/or consistent changes for the mRNA expression signal of FGF-BP2 in the 
melanoma cell lines 1205LU or SK-MEL5. Also, the FGF-BP2 transfected SW-13 cell 
line did not show any response in its FGF-BP2 signal after treatment with retinoic acid 
(Results 4.8.2, Figure 18). This evidence stresses the observation that FGF-BP2 not only 
shows no transcriptional down-regulation by retinoic acid, but that also no 
posttranscriptional decrease of the FGF-BP2 RNA seems to be present. These facts, as 
determined by Northern Blotting analysis, clearly disclose that FGF-BP2 does not seem 
to be a target for down-regulation by retinoic acid, at least in none of the so far known 
tumor cell lines that express its mRNA. This data, together with the findings from the 
FBS, TPA and EGF- Northern Blotting experiments, make it clear that the FGF-BP2 
mRNA regulation is different from what is known about FGF-BP1. So far, we now 
understand that FGF-BP2 is not influenced by the regulators of FGF-BP1, but we do not  
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know if, and by what it may be regulated. However, again it seems valuable to 
comprehend that these two FGF binding proteins experience a difference in their 
regulation by retinoic acid. From the fact that FGF-BP2 is not influenced by retinoic acid 
and therefore able to fulfill its potential role as an activator of immobilized FGFs one can 
conclude, that this might be a reason for non-responding of skin carcinomas to treatment 
with retinoic acid.  
 
 
5.8 Tumorigenic Activity of FGF-BP2 transfected SW-13 Cells in Soft Agar Assays 
 
The biological activity of FGF-BP1 transfected SW-13 cells in soft agar assay, indicating 
the tumorigenic potential of the binding protein, has been a well studied experimental 
model in the past. Previously Czubayko et al. (Czubayko et al.,1994) were able to show 
that SW-13 FGF-BP1 transfected cells grow large colonies in soft agar compared with 
cells transfected with the empty vector. To test whether endogenous bFGF was 
stimulating the SW-13 FGF-BP1 transfected cells through an autocrine mechanism, a 
neutralizing monoclonal antibody specific for bFGF was included in the assay. Treatment 
with the α-bFGF antibody at a concentration of 1 µg/ml blocked colony formation of the 
FGF-BP1 transfected SW-13 cells almost completely, indicating that indeed bFGF was 
the driving force of autocrine growth after FGF-BP1 transfection. 
Ogawa et al., who characterized FGF-BP2 as a novel serum protein produced by 
cytotoxic lymphocytes were the first to publish the sequence similarity of FGF-BP1 and 
FGF-BP2 (Introduction 1.5; Ogawa et al., 2001). In their study they also tried to find 
functional similarities to FGF-BP1 but failed to do so (Discussion 5.2, 5.3). Ogawa et al. 
claim that in their study FGF-BP2 had no effect on the exogenous bFGF-dependent or on 
the spontaneous colony growth of SW-13 cells in soft agar.  
However, in the present work soft agar assays with FGF-BP2 transfectants were carried 
out similar to the FGF-BP1 experiments by Czubayko et al. In contrast to the findings of 
Ogawa et al., the data shown in Results 4.9 and Figure 20 revealed doubled colony 
formation by FGF-BP2 transfectants compared to the empty vector transfected cells.  
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However both transfected cell populations were stimulated to form more colonies in the 
presence of exogenous bFGF, especially at high exogenous bFGF concentrations the 
difference observed for the two cell populations was greatly diminished. This observation 
may be due to the fact that FGF-BP2 enhances the availability of active bFGF at low 
concentrations to cellular receptors, whereas at high concentrations the receptors are 
potentially saturated. Addition of an α-bFGF antibody resulted in reduced colony 
formation in FGF-BP2 transfectants to the same level as that of the untreated empty 
vector transfected cells, indicating that free bFGF is the controlling force for colony 
formation in the FGF-BP2 model. The observation that exogenous aFGF has the same 
effect on the colony formation as bFGF, although at relatively high aFGF concentrations, 
matches the observations of Esch et al., who were previously able to show that bFGF is 
biologically more potent than aFGF in the absence of heparin (Esch et al., 1985). 
This demonstrates that expression of this novel secreted binding protein activates one 
group of very potent angiogenesis factors, namely aFGF and bFGF, just like it is known 
for FGF-BP1. Both FGFs are typically not exported by cells into their medium, consistent 
with a lack of a secretory signal peptide (Burgess and Maciag, 1989). All in all one can 
say that similarly to the function previously ascribed to FGF-BP1 (Introduction 1.4, 
Figure 2, Czubayko et al., 1994, Czubayko et al., 1997, Rak and Kerbel, 1997), these data 
from the soft agar assays suggest that FGF-BP2 may be able to solubilize and activate 
endogenous matrix bound bFGF and allows it to reach its cellular receptors in the SW-13 
cell model system. 
This conclusion is based on the fact that the neutralizing α-bFGF antibody added to the 
cells in soft agar can inhibit the spontaneous colony formation of FGF-BP2 transfected 
SW-13 cells (Figure 20). Conceivably bFGF reaches the extracellular compartment, 
where it stimulates its receptors and can also be bound and neutralized by the added α-
bFGF antibody. In addition it was also possible show that FGF-BP2 is likely to be 
effective in presenting low concentrations of both exogenous aFGF and bFGF to their 
receptors to induce colony formation. 
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Figure 21: Models of FGF-BP2 Functions  
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Figure 21: Models of FGF-BP2 functions. Model I displays the mechanism of bFGF activation 
by FGF-BP2 that has previously been established for FGF-BP1: secreted FGF-BP2 binds to 
immobilized bFGF, which is stored in the extracellular matrix. bFGF is released in a soluble and 
bioactive form, allowing it to reach its target cell receptor and stimulate angiogenesis. (Adapted 
from Rak J. and Kerbel, R.S. (1997) bFGF and tumor angiogenesis – back in the limelight? 
Nature Med. 3, 1083-1084). Model II shows a possible alternative mechanism of bFGF activation 
by FGF-BP2: secreted FGF-BP2 prevents the binding of bFGF to matrix heparan sulfate 
proteoglycans and allows free bFGF to reach its target cell receptor and stimulate angiogenesis. 
 
 
This data of FGF-BP2 and its biological activity is fully compatible with the established 
model of FGF-BP1 displacing bFGF bound to matrix heparan sulfate proteoglycans and 
presenting it to its receptors. However, it is further complicated by the ability of FGF-
BP2 to bind to heparin-Sepharose (Q. Nguyen and A. Wellstein, unpublished data) and  
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therefore likely to interact with heparan sulfate proteoglycans. Since the interaction 
nature among bFGF, FGF-BP2 and heparan sulfate proteoglycans is not fully 
characterized, it is also possible that secreted FGF-BP2 prevents the binding of bFGF to 
matrix heparan sulfate proteoglycans in the first place and enables free bFGF to reach its 
receptors to mediate in vitro and in vivo its tumor promoting activities (Figure 21). This 
alternative mechanism of FGF-BP2 interaction with bFGF and the heparan sulfate 
proteoglycans was previously discussed for FGF-BP1, that not only binds to bFGF but 
also to heparan sulfate proteoglycans (Wu et al., 1991; Czubayko et al. 1994).On the 
other hand Aigner et al. were recently able to show that FGF-BP1 is more likely to bind 
to bFGF than to heparan sulfate proteoglycans (Aigner et al., 2001). However, for the 
novel FGF-binding protein it is at this point impossible to decide whether bFGF or FGF-
BP2 first bind to cellular heparan sulfate proteoglycans, although it is likely that the 
mechanism will be similar to what was revealed for FGF-BP1. Further experiments with 
cells deficient in heparan sulfate may be able to answer the question definitely. 
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Angiogenesis is one of the essential alterations in cell physiology that dictate 
malignant growth and metastasis and has long been a major focus in molecular 
cancer research. More than a dozen distinct proteins are currently known to induce 
proliferation of endothelial cells in vitro and/or angiogenesis in vivo. Some of the 
most effective and best-studied angiogenic factors are fibroblast growth factors 
(FGFs) that are potent stimulators of new blood vessel formation during tumor 
growth. However, some FGFs (aFGF and bFGF) are upon secretion immobilized in 
the extracellular matrix (ECM) and unable to reach their high affinity receptors. 
There are several possible mechanisms by which bFGF can be released from its 
matrix storage site and thus activated. One established mechanism is the action of 
an FGF binding protein (FGF-BP1). FGF-BP1 activates bFGF and is thus able to 
stimulate tumor cell proliferation and angiogenesis. Recently a human cDNA clone 
containing an open reading frame for a protein, which shows amino acid sequence 
similarity of 21% and  homology of 41 % to FGF-BP1 was discovered. This novel 
molecule was named FGF-BP2.  
In this study the FGF-BP2 expression profile under physiological conditions in 
normal human tissue and in the pathological setting of tumor cell lines was 
evaluated by Northern Blotting analysis. Following its in vitro gene regulation by 
various drugs and growth factors was studied. Finally the FGF-BP2 cDNA was 
cloned into an expression vector, the gene was overexpressed in the human adrenal 
carcinoma cell line SW-13 and then analyzed for its tumorigenic potential in soft 
agar growth assays.  
This study revealed a widespread FGF-BP2 mRNA expression in normal human 
tissue. Among 36 tumor cell lines tested though, FGF-BP2 mRNA expression was 
limited to all of the melanoma cell lines. Interestingly, no FGF-BP2 mRNA 
expression was detected in normal human neonatal melanocytes. Furthermore it 
was evaluated if some of the well defined mechanisms for gene regulation that are 
known for FGF-BP1 also exist for FGF-BP2 as tested in two melanoma cell lines. 
However, in contrast to what is known for FGF-BP1 it was neither possible to show 
a significant up-regulation of the FGF-BP2 mRNA expression by Fetal Bovine  
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Serum, EGF and TPA, nor was any down-regulation inducible by all-trans retinoic 
acid. Finally it was shown that FGF-BP2 overexpression in the human adrenal 
carcinoma cell line SW-13 promotes a bFGF-dependent colony formation in vitro, 
indicating its tumorigenic potential.  
This study demonstrates that the novel FGF-binding protein has not only structural 
but also functional similarities to FGF-BP1. Its biological activity, together with 
other data that are not presented here suggest that FGF-BP2 is like FGF-BP1 a 
tumor promoting agent that may solubilize matrix bound bFGF. However, FGF-
BP2 shows a different expression pattern from FGF-BP1 and does not seem to 
follow similar mechanisms of transcriptional or posttranscriptional gene regulation. 
Most interesting though seems to be the function that FGF-BP2 might have in 
melanoma progression since it is known that bFGF and its activated signal pathway 
play a crucial role in the development of melanoma.  
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         8. ABBREVIATIONS  
 
 
aFGF (FGF-1)    Acidic Fibroblast Growth factor 
bFGF (FGF-2)   Basic Fibroblast Growth Factor 
bp     base pair 
BP     Binding Protein 
BSA     bovine serum albumin 
cDNA      complementary DNA 
cpm     counts per minute 
dCTP      desoxycytosin tri-phosphate 
DEPC     diethylpyrocarbonate 
DMSO     dimethylsulfoxide 
DNA      desoxyribonucleic acid 
ECM     Extracellular Matrix 
EDTA     etylendiamine tetraacedic acid 
EGF     Epidermal Growth Factor 
FBS     Fetal BovineSerum 
GAPDH    glyceraldehyd-3 phosphat dehydrogenase  
HGF     Hepatocyte Growth Factor 
IMEM     Improved Minimal Essential Medium 
kb     kilo base 
LB     Luria-Bertani 
MOPS     3-(N-morpholino)propanesulfonic acid  
ORF     open reading frame 
PCR     polymerase chain reaction 
PTN     Pleiotrophin 
Abbreviations  107 
RNA     ribonucleic acid 
SCC     Squamous Cell Carcinoma 
SDS     sodium dodecyl sulfate 
SSC     sodium chloride/sodium citrate 
ssDNA    single stranded desoxyribonucleic acid 
TBE     Tris-base/ boric acid/ EDTA 
TGFα     Transforming Growth Factor Alpha 
TPA     12-O-tetradecanoyl phorbol 13-Acetat 
tRA     all-trans-retinoic acid 
VEGF     Vascular Endothelial Cell Growth Factor 
